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ABSTRACT 
 
             Head and neck squamous cell carcinomas contain a sub-population of 
highly tumorigenic cells that exhibit self-renewal and multipotency. These cells 
can be isolated from primary head and neck squamous cell carcinomas using 
Aldehyde Dehydrogenase (ALDH) activity and CD44 expression, and have been 
named head and neck cancer stem cells (HNCSC). It has been proposed that the 
HNCSC are the “drivers” of head and neck tumor progression, and therefore 
have to be eliminated to achieve cancer cure. However, little is known about 
mechanisms underlying the survival and self-renewal of HNCSC. The hypothesis 
underlying this dissertation is that head and neck cancer stem cells (i.e. 
ALDH+CD44+) are localized in the perivascular niche and depend on endothelial 
cell-secreted factors for their survival and self-renewal. 
Here, we observed that HNCSC are found in close proximity to blood 
vessels in primary head and neck squamous cell carcinomas. Endothelial cell-
secreted factors promoted the proliferation, self-renewal and survival of HNCSC 
in vitro, as evidenced by the increase in number of orospheres (i.e. non-adherent 
colonies of cells) formed in soft agar or ultra-low attachment plates. In vivo, 
selective ablation of tumor endothelial cells caused a marked decrease in the 
fraction of HNCSC suggesting that cancer stem cells depend on intact 
perivascular niches for their survival. 
xiv 
 
In our search for a possible mechanism to explain the dependency of 
HNCSC on endothelial cells, we observed that cancer stem cells have a 
constitutively active IL-6R/STAT3 pathway, while tumor endothelial cells secrete 
high levels of IL-6. Inhibition of endothelial cell IL-6 caused a decrease in the 
self-renewal and tumorigenicity of the HNCSC. Notably, a humanized antibody to 
IL-6R delayed tumor initiation and decreased the survival of HNCSC in vivo. 
Collectively, these results unveil the endothelial cell-secreted factors as critical 
regulators of HNCSC survival and self-renewal, and suggest that patients with 
head and neck cancer might benefit from targeted therapies against cancer stem 
cells.  
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CHAPTER I 
 
INTRODUCTION 
 
 
Cancer Cell Biology: Clonal vs Cancer Stem Cell 
          Tumors are not insular masses of proliferating cells (Hanahan and 
Weinberg, 2000). Instead, a tumor can be seen as an “organ” composed of 
transformed cells that interact with stromal cells within the tumor 
microenvironment (Figure. 1.1). The understanding of cancer as a complex 
tissue where tumor cells rely on interactions with stromal cells to progress 
towards malignancy and overcome host defenses has been solidified by 
extensive research in the last decade (Hanahan and Weinberg, 2011). 
Collectively, this work suggested that not all tumor cells are equal. Indeed, 
malignant cells with different tumorigenic potential have been found in many 
tumor types. The possibility of identifying those cells with higher tumorigenic 
potential, and selectively eliminating them, is the clinical rationale underlying this 
work. 
          According to the stochastic hypothesis, tumor cells are homogeneous, i.e. 
every cancer cell has equal propensity to initiate and propagate tumors and 
metastasize. In effect, it means that there is no selectivity between the cancer 
cells in a tissue; each cell has the same potential to initiate tumors. The 
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heterogeneity in tumors is explained by spontaneous shifts in cell phenotypes 
(Albers et al., 2011). However, emerging evidence from a variety of tumors 
suggests an alternative explanation called the “cancer stem cell” hypothesis. It 
states that the tumor tissue has a distinct hierarchy of cells and only a small sub-
population of cells within the tumor is capable of initiating cancers. These are 
called cancer stem cells or “tumor-initiating cells” (Reya et al., 2001). The bulk of 
the tumor tissue, however, is composed of rapidly proliferating cells called transit-
amplifying cells and post-mitotic differentiated cells, which do not contribute to 
tumor initiation. These cells are derived from the cancer stem cells by 
differentiation but do not cause tumor initiation by itself.   
          Following these two alternate models of study, extensive work has been 
done to understand them in different tumors. Recently, it was demonstrated in 
melanomas that about 25% of unselected melanoma cells were able to create 
tumors in immunocompromised mice, suggestive of a more stochastic model 
(Quintana et al., 2008). However, in recent literature, evidence to the contrary 
has been seen. CD271positive cells in melanomas were able to create tumors 
more likely than the negative cells supporting the cancer stem cell hypothesis 
(Civenni et al., 2011). In another independent study, CXCR6+ cells created more 
aggressive tumors than not (Taghizadeh et al., 2010). This suggests the 
existence of primitive melanoma cells capable of phenotypic plasticity, self-
renewal and immune evasion (Girouard and Murphy, 2011). A number of 
features of HNSCC can also be explained using the stochastic model. The 
existence of large pre-neoplastic areas beyond the surgical margins results in 
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local recurrences and secondary cancers which are explained by the stochastic 
model (Albers et al., 2011). On the other hand, the heterogeneity seen in the 
head and neck cancers and distant metastasis supports the cancer stem cell 
hypothesis (Prince et al., 2007; Chen et al., 2009). 
          One of the earliest studies exploring the tumorigenic potential of cells 
showed that a single tumor cell from one mouse generated a tumor in a 
secondary recipient mouse (Furth and Kahn, 1937). The idea of tumor-initiating 
cells was further explored in leukemia where low numbers of leukemic cells 
generated tumors in mice (Hewitt et al., 1958; Bonnet et al., 1997). The tumors 
generated in these studies were heterogeneous with a hierarchical organization 
suggestive of cells with varying degrees of tumorigenicity. Importantly, a study 
involving the labeling of mouse squamous cell carcinoma cells with tritiated 
thymidine showed that undifferentiated malignant cells are capable of generating 
non-tumorigenic keratinocytes (Pierce et al., 1971). These results suggested that 
not all progeny of malignant cells is tumorigenic. Further support for the presence 
of a small sub-population of cells with higher tumorigenic potential came from 
studies which reported that only 1-4% of lymphoma cells formed colonies in 
spleen, and only about 0.02-0.1% of solid tumor cells formed colonies 
(Hamburger et al., 1977).  
          In the late 1970’s however, the focus of cancer biology shifted to the 
concept of clonal evolution as mutations in oncogenes and tumor suppressors 
were found to cause human cancers. Tumor cell populations were considered 
genetically unstable and acquisitions of genetic mutations created human 
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malignancies. The step-wise genetic mutations that certain genes acquired in 
colon cancer was well documented by the Vogelstein laboratory (Fearon et al., 
1990). However, in the early nineties, technological advances allowed for studies 
that again suggested a hierarchy of tumorigenic potential of tumor cells. Such 
studies were facilitated with the advent of technologies such as the Fluorescence 
Activated Cell Sorting system (FACS), which enabled researchers to study 
specific cell surface markers in individual cells and use these markers to sort pre-
determined sub-populations of cells. For example, FACS helped in identifying 
that leukemic engraftment was possible only with CD34+CD38- expressing cells 
(Bonnet et al., 1997). Xenograft assays further demonstrated that only one in a 
million cells was capable of initiating tumors in acute myeloid leukemia (Lapidot 
et al., 1994). Notably, the hierarchical concept and the step-wise concept are not 
mutually exclusive. Rather, these two theories may have a different impact in 
different stages of tumor progression.  
Cancer Stem Cell Hypothesis 
          It is well known that most human tissues (e.g. brain, skin, and intestine) 
contain stem cells (Blainpain et al., 2004; Vries et al., 2010). The cancer stem 
cell hypothesis is fundamentally based on the application of stem cell concepts 
derived from embryogenesis to understanding of the tumorigenic process. The 
following are key features of the cancer stem cell hypothesis: “(1) only a small 
fraction of the cancer cells within a tumor have tumorigenic potential when 
transplanted into immunodeficient mice; (2) the cancer stem cell sub-population 
can be separated from the other cancer cells by distinctive surface markers; (3) 
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tumors resulting from the cancer stem cells contain the mixed tumorigenic and 
non-tumorigenic cells of the original tumor; and (4) the cancer stem cell sub-
population can be serially transplanted through multiple generations, indicating 
that it is a self-renewing population” (Prince and Ailles, 2008). Therefore, cancer 
stem cells are capable of self-renewal and differentiating into other distinctive 
cells that make up the tumor mass (Reya et al., 2001).  
          The fundamental concept underlying the cancer stem cell hypothesis is 
that not all tumor cells in a cancer are equal. Indeed, in a landmark publication, 
Clarke’s laboratory showed that breast tumors were heterogeneous and as few 
as 100 CD44+CD24-/low cells isolated from primary breast cancers were capable 
of initiating tumors, whereas tens of thousands of phenotypically different cells 
did not (Al-Hajj et al., 2003). An important observation of this study was that the 
resulting xenografts had distinct sub-populations of cells reproducing the 
heterogeneity of the original tumors (suggestive of the multipotency of the tumor-
initiating cells), and consistently expressed specific cell surface markers that 
were used to identify the cancer stem cells (indicative of self-renewal capability of 
these cells). In recent years, head and neck squamous cell carcinomas have 
been studied in great detail to identify whether it abides by the cancer stem cell 
hypothesis or the stochastic model. Such knowledge has major implications to 
cancer therapy, as will be discussed later. 
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Head and neck squamous cell carcinomas 
          The immense cancer mortality rate worldwide requires that strategies be 
developed to detect cancers earlier, understand better, treat more effectively and 
prevent recurrences. Head and neck squamous cell carcinoma (HNSCC) ranks 
sixth worldwide for cancer-related mortality, with estimated 500,000 new cases 
diagnosed every year (Vermorken et al., 2007). More than 30,000 new cases of 
head and neck cancers are diagnosed in the United States alone (Jemal et al., 
2007). This includes malignant lesions in the oral cavity, larynx and pharynx. For 
the past several decades the mainstay of treatment for HNSCC has been surgery 
and radiation. Though the standard therapy cures significant number of patients 
with Stage I disease, more than 23% develop secondary primaries, relapse and 
die (Larson et al., 1990). For more advanced stages of the disease, the survival 
rate has not improved significantly in the last couple of decades. The use of 
platinum based therapy has improved local control of the disease, but the 
incidence of distant metastases appears to be in the rise in recent years 
(Forastiere, 2008; Sano et al., 2007). It is possible that cancer stem cells 
participate in the processes that lead to resistance to therapy and the 
establishment of distant metastases. 
          Several risk factors have been associated with the development of 
HNSCC. The most common among them are carcinogen exposure, tobacco use, 
oral hygiene and family history. Tobacco, however, is the single most common 
risk factor for HNSCC (Brennan et al., 1995, Ho et al., 1997, Zhang et al., 2000). 
Alcohol consumption as a risk factor is most commonly seen to be amplifying the 
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effects of tobacco in a synergistic manner (Talamini et al., 2002). In recent years, 
the role of human papillomavirus as a causative agent in HNSCC has increased 
tremendously (Gillison et al., 2000, Mork et al., 2001, Herroro et al., 2003).   
          The initiation and progression of head and neck cancers has been thought 
for a long time to be an effect of acquisition of various genetic and epigenetic 
alterations (Califano et al., 1996). In fact, 40 – 60% of patients with HNSCC 
present with a mutation of the p53 gene (Hollstein et al., 1991, Poeta et al., 
2007). In more recent years, the epidermal growth factor receptor (EGFR) has 
been found to be highly expressed in more than 95% of HNSCC and has been 
associated with poorer prognosis (Kalyanakrishna and Grandis, 2006). These 
genetic alterations led credence to the clonal evolution or stochastic hypothesis 
in HNSCC until recently.  
Cancer stem cells in head and neck tumors 
          In a landmark publication, Prince and collaborators (2007) unveiled the 
presence of highly tumorigenic, stem-like cells, in HNSCC. They analyzed 
HNSCC using FACS sorting for expression of CD44, and were able to generate 
tumors with as few as 5×103 cells of CD44+ cells whereas higher numbers of 
CD44- cells failed to create tumors. They were also able to show that the 
resultant xenografts were heterogeneous (Prince et al., 2007). These data lend 
support to the concept that HNSCC follows the cancer stem cell hypothesis, 
where sub-populations of cancer cells have significantly higher tumorigenic 
potential than others.  
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Identification of cancer stem cells in head and neck tumors 
          Identification and isolation of cancer stem cells constitutes a major 
experimental challenge. Researchers attempt to isolate these cells by identifying 
properties that distinguish stem cells from their differentiated progeny and from 
stromal cells. These properties include the efflux of vital dyes by multidrug 
transporters (e.g. ABC transporters), enzymatic functions (e.g. Aldehyde 
Dehydrogenase activity), the sphere forming capacity in low attachment 
conditions, and the expression of cell surface antigens.  
          Prince et al. (2007) demonstrated that CD44 serves as a cancer stem cell 
marker in HNSCC. CD44, a cell surface glycoprotein functions as receptor for 
hyaluronic acid, is involved in cell adhesion and migration (Gao et al., 2011). 20 
out of 30 implantations of CD44+ cells were able to create tumors in 
immunodeficient mice, whereas only one of 40 implantations of CD44-cells 
generated tumors (Prince et al., 2007). Following this work, several independent 
groups confirmed that CD44 either alone or in combination has the properties of 
cancer stem cell marker and being a tumor initiator (Baumann et al., 2010; 
Chikamatsu et al., 2011). Emerging literature is revealing a role for CD44 in 
tumor metastasis. Indeed, it has been described that certain forms of CD44 (i.e. 
v3, v6, v10) are associated with tumor progression and metastatic spread of 
HNSCC (Wang et al., 2009). It has also been shown that CD44+ cells express 
high levels of Bmi-1 (Prince et al., 2007), a self-renewal protein found in 
embryonic stem cells (Bracken et al., 2006).  
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           The transmembrane glycoprotein CD133 has also been investigated as a 
putative marker for cancer stem cells (Wu et al., 2009). CD133 or Prominin-1 
originally found on neuroepithelial stem cells in mice, was first isolated in humans 
from the hematopoietic stem cells by a monoclonal antibody recognizing a 
specific epitope called the AC133 (Shmelkov et al., 2005). In some HNSCC cell 
lines (e.g. hep-2), CD133+ cells were found to have increased clonality, i.e. the 
ability to form clones of cells from a single cell in suspension, when compared to 
CD133-cells (Zhou et al., 2007). Oral cancer-enriched cells from cell lines and 
primary tumors were found to have an increased expression of CD133 and 
displayed increased migration, and tumorigenicity (Chiou et al., 2008). In fact, 
correlation of Oct-4, Nanog and CD133 status showed a poorer prognosis of oral 
cancer patients with increased CD133 expression (Chiou et al., 2008). Recently, 
CD133+ cells were found to possess increased clonogenicity, invasiveness and 
tumorigenicity as compared to CD133- cells along with resistance to paclitaxel 
(Zhang et al., 2010).   
          Aldehyde Dehydrogenase (ALDH) is an intracellular enzyme that is 
involved in converting retinol to retinoic acid (Sobreira et al., 2011). In cancer, 
ALDH+ cells were initially identified in breast and brain (Ginestier et al., 2007; 
Rasper et al., 2010). In these tumors, ALDH+ cells were characterized as highly 
tumorigenic cells that can self-renew, which are hallmarks of cancer stem cells. 
In HNSCC, ALDH enriches for cancer stem cells and is involved in epithelial to 
mesenchymal transition (EMT) (Chen et al., 2009). Interestingly, a recent report 
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demonstrated that as few as 500 ALDH+ cells were able to create tumors unlike 
the ALDH- cells (Clay et al., 2010).  
          The ability of cells to actively pump out dyes like the Hoechst 33342 by the 
ATP-binding cassette transporter (ABC) has also been used to identify cells with 
increased longevity. As stem cells and cancer stem cells can remain quiescent 
for long terms, it has been used to identify potential cancer stem cells. Side 
population cells in HNSCC have been shown to increase clonality and 
tumorigenic potential (Zhang et al., 2009). 
 
Stem cell niche 
          Physiological stem cells and cancer stem cells depend on their immediate 
microenvironment or niche for their survival and function (Borovski et al., 2011). 
The niche provides cues that regulate proliferative and self-renewal signals 
thereby helping cancer stem cells maintain their undifferentiated state (Kuhn and 
Tuan, 2010). The non-epithelial stromal cells, inflammatory cells, and the 
vasculature have been proposed as key components of the niche that support 
and sustain cancer stem cells (Fuchs et al., 2004). Based on this knowledge, 
cancer stem cells are being targeted for therapy using their niche. Recently, it 
was shown that hematopietic stem cell niche could be targeted for metastatic 
bone tumors (Shiozawa et al., 2011).  
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 In HNSCC, studies are required to elucidate the existing niches. 
Endothelial cells present in the perivascular niche provide critical survival and 
self-renewal cues for cancer stem cells in glioblastomas (Calabrese et al., 2007).  
Therapeutic implications and significance of cancer stem cells in HNSCC 
          The cancer stem cell hypothesis has significant implications in the 
management of patients with cancer. It tells us that tumor tissue is 
heterogeneous and that the sub-population of cancer stem cells is primarily 
responsible for tumor initiation. It also implies that the bulk of the tumor tissue 
might be relatively innocuous compared to the highly tumorigenic cancer stem 
cells. Importantly, cancer stem cells tend to be very resilient and resistant to 
conventional therapies (chemotherapy and radiation therapy) that are targeted at 
highly proliferative cells (Chikamatsu et al., 2011). It has been postulated that 
cancer stem cells can remain quiescent for extended periods of time, and 
therefore escape from conventional treatment protocols. However, these cells 
have the potential to become activated, differentiate and proliferate leading to the 
establishment of local recurrences or distant metastases.  
          In Figure 1.2, we propose a hypothetical model for the response of 
HNSCC to different therapeutic strategies. HNSCC is represented as a complex 
tissue where the cancer stem cells constitute a relatively small number of cells 
that are capable of undergoing self-renewal and differentiating into a complex 
and heterogeneous tumor. Conventional chemotherapeutic drugs are successful 
in de-bulking the tumor. However, it is proposed that slow-growing cancer stem 
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cells evade conventional therapies and, with passage of time, these cells are 
activated and regenerate tumors locally or at distant sites (Figure 1.2A). This 
might explain the relatively high recurrence rates in patients with HNSCC. On the 
other hand, targeting of the cancer stem cells either directly (Figure 1.2B) or via 
their niche (Figure 1.2C) could lead to a more definitive cure, as the cancer stem 
cells are the putative drivers of recurrence and metastatic spread. An emerging 
concept is the combined use of conventional chemotherapy and cancer stem 
cell-targeted therapy. This drug combination is appealing since such strategy 
could potentially allow for tumor de-bulking (with conventional drugs) and 
prevention of recurrence/metastases (cancer stem cell-targeted drugs).  
          Extensive work is being done to understand the molecular mechanisms 
that might be playing a role in the pathobiology of cancer stem cells but not in 
normal cells, which would allow specific targeting of pathological cells. One such 
target could be Bmi-1, present in high levels in cancer stem cells (Hayry et al., 
2010). Several other signaling pathways (e.g. Wnt, PTEN, Notch, Hedgehog) are 
also currently being explored as potential therapeutic targets (Pannuti et al., 
2010; Takahashi-Yanaga and Kahn 2010; Takazaki et al., 2011). Various 
laboratories are isolating cancer stem cells and performing gene array analyses 
to understand how cancer stem cells might be differentially regulated compared 
to the rest of the tissue. Certain early studies suggest the role of micro-RNA like 
the Let7, Micro-RNA-200 in cancer stem cells to be an important player (Lo et al., 
2011; Yu et al., 2011). The ability to selectively target cancer stem cells, while 
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sparing normal stem cells, will be critical for the future application of the cancer 
stem cell therapy in the clinic.  
          Another important conceptual strategy for targeted elimination of cancer 
stem cells is through the disruption of their supportive niche. In glioblastoma 
models, the use of anti-angiogenic therapies correlated with a decrease in cancer 
stem cell fraction (Calabrese et al., 2007). Collectively, these results demonstrate 
that by interfering with the cancer stem cell microenvironment (i.e. the niche); 
one can compromise the ability of these cells to survive and/or to behave as a 
stem cell. These data suggest that therapies like anti-angiogenic agents might 
have the unexpected, yet most welcome, effect of decreasing the presence of 
highly tumorigenic cancer stem cells. However, recent evidence demonstrated 
that anti-angiogenic therapy (especially anti-VEGF based therapy) causes a 
malignant progression of tumors resulting in increased tumors and metastasis 
due to increased tumor cell infiltration (Paez-Ribes et al., 2009; Keunen et al., 
2011). More studies are thereby necessary to understand and develop specific 
targeting molecules against cancer stem cells. 
Challenges facing head and neck cancer stem cell research 
          One of the biggest challenges in cancer stem cell research has been 
development of methods for culture, expansion, and analyses of undifferentiated 
cancer cells in vitro. The property of surviving in suspension (anchorage 
independence) has been used for this purpose (Jensen and Parmar, 2006). The 
method of enriching for cancer stem cells using sphere generation under low 
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attachment conditions has been proposed and used in various cancer models 
like the breast, neural and prostate (Dontu et al., 2003, Pastrana et al., 2011). In 
this case, putative cancer stem cells are cultured either in a matrix-based assay 
like soft agar or in low attachment plates.  
          Despite intense research in the area of cancer stem cell biology in recent 
years, the understanding of the impact of cancer stem cells to the pathobiology of 
HNSCC is still quite primitive. One of the reasons for this is the need to perform 
most studies with primary HNSCC specimens, which are difficult to obtain. There 
is still controversy over the existence of cancer stem cells in cell lines, despite 
the fact that independent reports have shown cancer stem-like cells in cell lines 
(Harper et al., 2007; Gammon et al., 2011). In addition, the expansion of cancer 
stem cells is frequently performed in vivo, which is time consuming and 
expensive. However, existing in vitro methods offer limited capacity for expansion 
of cancer cells in an undifferentiated state. It has become clear that the 
development of improved methods for isolation and expansion of head and neck 
cancer stem cells is imperative for the acceleration of the pace of discovery in 
this area. 
Statement of purpose 
          More than half a million new cases of HNSCC are diagnosed every year 
world-wide. Despite extensive research, the 5-year survival rate for these 
patients has been low and has not significantly improved over the last couple of 
decades. The discovery of a small sub-population of cells that possess 
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exquisitely high tumorigenic potential, associated with the possibility of identifying 
these cancer stem cells in clinical settings, provides a new conceptual target for 
cancer therapy. It is well known that a frequent cause of failure of conventional 
therapy in HNSCC is the high incidence of local recurrence and distant 
metastasis. Notably, it has been hypothesized that conventional therapies do not 
eliminate the slow growing cancer stem cells, which appear to be the “drivers” of 
tumor recurrence and metastases. Therefore, the recent observation that 
HNSCC follows the cancer stem cell hypothesis suggests that targeted 
elimination of these tumor-initiating cells might prevent tumor regrowth and 
distant disease. However, little is known about the cancer stem cells in HNSCC. 
The role of the niche and possible mechanisms by which the niche can promote 
the survival of the cancer stem cells in HNSCC has been completely unexplored. 
The overall goal of our study was to further characterize the existence of cancer 
stem cells in HNSCC, and the micro-environments it exists in. Emphasis was laid 
on trying to understand possible molecular mechanisms which might promote the 
survival of the cancer stem cells for possible therapeutics.  
           In this dissertation, we try to establish ALDH+CD44+ cells as cancer stem 
cells in HNSCC with increased tumorigenicity and self-renewal and develop in 
vitro assays to study them in Chapter II. We tested the tumorigenicity of these 
cells and explore the possible micro-environments or niches that they reside in 
HNSCC.   The observation that the endothelial cells promoted active proliferation 
and survival of the cancer stem cells in Chapter III led us to explore the signaling 
pathway in this interaction. We studied using gene silencing techniques and 
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transgenic mouse models, the role of the inflammatory cytokine, IL-6 in the 
interaction between the endothelial cells and the head and neck cancer stem 
cells. More specifically, we were able to demonstrate that perturbation of the IL-
6-IL-6R signaling pathway with a humanized antibody delayed the tumorigenicity 
of the head and neck cancer stem cells by decreasing their survival in Chapter 
IV.  
Hypothesis 
The central hypothesis addressed in this dissertation is that head and 
neck cancer stem cells exist in vascular niches and that endothelial cell initiated 
signaling pathways promote the self-renewal and tumorigenicity of the cancer 
stem cells in head and neck cancers. 
 
Specific Aims 
The following specific aims were addressed to answer the central hypothesis: 
- Specific Aim 1: To develop novel in vitro “Orosphere assays” to study 
and propagate head and neck cancer stem cells i.e., ALDH+CD44+cells 
(Chapter II). 
- Specific Aim 2: To identify a peri-vascular niche and to study the effects 
of endothelial cell-initiated signaling on the survival and self-renewal of 
head and neck cancer stem cells (Chapter III). 
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- Specific Aim 3: To study the effect of endothelial cell initiated IL-6 
signaling on the self-renewal, survival and tumorigenicity of cancer stem 
cells (Chapter IV) 
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Figure 1.1. Cancer tissue is a complex “organ”. The tumor tissue 
microenvironment is composed of a variety of cells including tumor cells, cancer 
stem cells, inflammatory cells, cancer-associated fibroblasts along with blood 
vessels. The cancer stem cells are rare cells found primarily in the invasive edge 
of tumors in supportive niches.  
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Figure 1.2. Possible implications of the cancer stem cell hypothesis to 
therapy. (A), Conventional chemotherapy targets primarily the highly proliferative 
cells that constitute the bulk of the tumor. With suitable microenvironments, the 
cancer stem cells proliferate and the tumor recurs. (B), Direct cancer stem cell 
targeting or (C), indirect cancer stem cell targeting via disruption of (e.g.) their 
perivascular niche can potentially eliminate cancer stem cells. Ablation of the 
stem cells may inhibit the regeneration of the tumor and ultimately result in tumor 
regression.   
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CHAPTER II 
 
OROSPHERE ASSAY: A METHOD FOR PROPAGATION OF HEAD AND 
NECK CANCER STEM CELLS 
 
 
Abstract 
 
Recent evidence suggests that head and neck squamous cell carcinomas 
(HNSCC) harbor a small sub-population of highly tumorigenic cells, named 
cancer stem cells. A limiting factor in cancer stem cell research is the intrinsic 
difficulty of expanding cells in an undifferentiated state in vitro. Here, we describe 
the development of the orosphere assay, a method for the study of putative head 
and neck cancer stem cells. An orosphere is defined as a non-adherent colony of 
cells sorted from primary HNSCC or from HNSCC cell lines and cultured in 3-D 
soft agar or ultra-low attachment plates. Aldehyde dehydrogenase (ALDH) 
activity and CD44 expression were used here as stem cell markers. This assay 
allowed for the propagation of head and neck cancer cells that retained stemness 
and self-renewal. The orosphere assay is well suited for studies designed to 
understand the pathobiology of head and neck cancer stem cells. 
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Introduction 
The cancer stem cell hypothesis provides a plausible mechanism for 
tumor recurrence and metastatic spread (Mimeault et al., 2010). According to the 
cancer stem cell hypothesis, a small sub-population of cancer cells is highly 
tumorigenic, capable of self-renewal and multipotency (Reya et al., 2001). Cells 
with such features may constitute the “drivers” of the tumorigenic process. If this 
hypothesis were indeed true for head and neck squamous cell carcinomas 
(HNSCC), selective targeting of these cancer stem cells would be essential to 
improve patient outcomes. Following the discovery of cancer stem cells in 
HNSCC (Prince et al., 2007), investigators throughout the world have begun 
studies to understand the pathobiology of these cells. The development and 
optimization of a method for in vitro expansion of head and neck cancer stem 
cells in an undifferentiated state would be beneficial for the progress of research 
in this area, and hopefully will accelerate the process of developing improved 
treatment modalities for HNSCC. 
Two cardinal properties of stem cells allow for their identification and 
purification: A) Self-renewal, i.e. the ability of stem cells to self-perpetuate; and 
B) Multipotency, i.e. the ability of cells to undergo differentiation and generate the 
complex cellular components observed in a tissue/organ or in cancer (Rudland et 
al., 1998, Weissman 2000, Morrison et al., 1997). It is possible to maintain 
human head and neck cancer stem cells in an undifferentiated state by serially 
passaging them in vivo, in immuno-deficient mice (Prince et al., 2007).  However, 
this strategy is time consuming and expensive. Furthermore, it is difficult to 
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perform mechanistic studies of signaling pathways involved in the biology of 
cancer stem cells exclusively in animal models. A third property of stem cells, i.e. 
the ability to form spheres and grow under low attachment conditions (Dontu et 
al., 2005), inspired the development of in vitro assays for the study of normal and 
cancer stem cells. 
Exploiting the fact that stem cells possess anchorage independence, i.e. 
the ability to survive and proliferate in suspension cultures unlike the non-stem 
cells (Reynolds and Weiss, 1996, Dontu et al., 2003), adherent-free culture 
conditions have been proposed as basis for in vitro assays for propagation of 
cancer stem cells. Suspension cultures have been utilized as a method to study 
stem cell properties in several tumor types, including those of the breast and 
brain (Reynolds and Weiss, 1992, Dontu et al., 2003, Hemmati et al., 2003). 
Most of these suspension cultures are done in 3-dimensional structures, such as 
soft agar matrices or dishes coated with fibronectin or matrigel (Miskon et al., 
2010, Stenberg et al., 2011, Denning et al., 2006). These strategies allow for 
stem cell expansion and proliferation making them a valuable assay for self-
renewal. However, the setup of these cultures is technically challenging, and the 
intrinsic difficulty associated with the retrieval of these cells from their matrix 
makes this method not ideal when mechanistic studies involving serial 
passaging, flow cytometry or gene expression analyses, are required. In an 
attempt to address such issues, the culture of cells in low-attachment plates has 
been proposed as an alternative strategy to deprive cells from anchorage, while 
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facilitating their retrieval of cells for further analysis (Deleyrolle et al., 2009, Dev 
et al., 2009, Zhang et al., 2011). 
Fluorescence Activated Cell Sorting (FACS) and magnetic bead sorting 
are common approaches for the identification and isolation of putative stem cells 
(McLelland et al., 2011, de Wynter et al., 1995). Using FACS, we observed that 
the fraction of putative cancer stem cells in primary HNSCC is small (Chapter III). 
Here, we describe a method for the propagation of head and neck cancer stem 
cells named the orosphere assay. The name reflects the fact that this method 
was optimized for studies of stem cells sorted from tumors or cell lines derived 
from the oral cavity and head and neck region. This method enables the 
expansion of cancer stem cells in an undifferentiated state by culturing them in 
ultra-low attachment plates or in 3-D soft agar matrices. The use of ultra-low 
attachment plates allowed for serial passaging of cells (i.e. demonstration of self-
renewal), and for the retrieval of cells for mechanistic studies.  
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Materials and methods 
Sorting and culture of head and neck cancer stem cells 
Head and neck squamous cell carcinoma cells (UM-SCC-74A, UM-SCC-
74B; gift from Dr. Carey, University of Michigan) were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM; Invitrogen; Grand Island, NY, USA), 10% fetal 
bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin. The identity of the 
tumor cell lines was confirmed by genotyping at the University of Michigan DNA 
sequencing core facility. Alternatively, putative cancer stem cells were isolated 
from a primary tumor, as described. Briefly, informed consent was obtained from 
an 81-year old female patient prior to surgical removal of a squamous cell 
carcinoma from the floor of the mouth. The specimen was cut into small pieces, 
minced until they passed through a 25 ml pipette tip, and suspended in a 9:1 
solution of DMEM-F12 (Hyclone, Waltham, MA, USA) containing collagenase 
and hyaluronidase (Stem Cell Technologies; Vancouver, BC, Canada). The 
mixture was incubated at 370C for one hour and passed through a 10-ml pipette 
every 15 minutes for mechanical dissociation. Cells were filtered through a 40-
μm nylon mesh (BD Falcon; Franklin Lakes, NJ, USA), washed with low glucose 
DMEM (Invitrogen) containing 10% FBS, and centrifuged at 800 rpm for 5 
minutes. Single cell suspensions obtained from primary specimens (as well as 
from HNSCC cell lines) were washed, counted, and re-suspended at 106 cells/ml 
PBS. The Aldefluor kit (Stem Cell Technologies) was used to identify cells with 
high ALDH activity. Briefly, cells were suspended in activated Aldefluor substrate 
(BAA) or in DEAB (specific ALDH inhibitor) for 45 minutes at 370C. Then, cells 
35 
 
were exposed to anti-CD44 antibody (clone G44-26BD; BD Pharmingen; Franklin 
Lakes, NJ, USA) and lineage markers eliminated (i.e. anti-CD2, CD3, CD10, 
CD16, CD18; BD Pharmingen). Viable cells are identified with 7-
Aminoactinomycin (7-AAD, BD Pharmingen). FACS (Fluorescence Activated Cell 
Sorting) sorted cells were cultured in low glucose DMEM (Invitrogen), 10% fetal 
bovine serum, and 100 U/ml Penicillin-streptomycin in low attachment conditions, 
as described below. Cells were defined as putative head and neck cancer stem 
cells (ALDH+CD44+) or control cells (ALDH-CD44-). To induce cell 
differentiation, FACS-sorted cells were cultured in regular tissue culture plates 
(BD Falcon). Studies were done in triplicate specimens per condition, and 
experiments were performed at least three independent times to verify 
reproducibility of the data.  
Orospheres in ultra-low attachment plates 
FACS-sorted cells (5x103 cells/well) were seeded in 6-well ultra-low 
attachment plates (Corning; New York, NY, USA) and cultured in low glucose 
DMEM, 10% fetal bovine serum and 100 U/ml Penicillin-streptomycin at 370C 
and 5% CO2. Orospheres were arbitrarily defined as a non-adherent colony of at 
least 25 cells. Orospheres can be mechanically dissociated into single cell 
suspensions and then re-seeded in new ultra-low attachment plates to generate 
secondary and tertiary orospheres (indicative of self-renewal).  
Orospheres in soft agar 
Alternatively, orospheres can be generated using low melting point 
agarose (Invitrogen). 6-well regular attachment plates (Fisher) were pre-coated 
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with a layer of 1.2% agarose mixed with equal volume of 2x DMEM (Invitrogen) 
to make an inert basal layer. This layer is solidified at room temperature for 30 
minutes. Then, 500 FACS-sorted cells/well were resuspended in 2x DMEM, 2.5% 
FBS, mixed with equal volumes of 0.6% agarose. After the second agarose layer 
gelifies at room temperature for 45 minutes, 500 µl low glucose DMEM 
(Invitrogen) is added onto the surface of the 3-dimensional matrix and cells are 
incubated at 370C thereafter. Usually the orospheres in soft agar are visualized 
after 7 days. Quantification of the number of orospheres/well is done under light 
microscopy. 
Immunocytochemistry 
For immunocytochemistry, 2x103 FACS-sorted cells/well were cultured in 
LabTek II Chamber Slide (Thermo Scientific; Rochester, NY, USA) for up to 7 
days. Antigen retrieval was performed using Dako Retrieval solution (S1699; 
Carpinteria, CA, USA) with gradual warming up from 400C to 980C within 40 
minutes. Slides were incubated in 3% hydrogen peroxidase for 10 minutes. 
Primary antibodies against Cytokeratin 17 (1:200; Abcam, ab2502; San 
Francisco, CA, USA) or Involucrin (1:200; Abcam ab27496) were incubated at 
40C overnight. Following a 20-minute incubation with appropriate secondary 
antibodies, the Romulin AEC Chromogen Kit (Biocare Medical; Concord, CA, 
USA) was used to visualize the proteins.  
Immunofluorescence and confocal imaging 
For confocal imaging, 2x103 FACS-sorted cells/well were seeded in a 24-
well ultra-low attachment plate for 3 days (Corning). Orospheres were fixed in 
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cold 10% buffered formalin (Fisher; Pittsburgh, PA, USA) for 30 minutes. For 
immunofluorescence, primary antibodies were pre-labeled with Alexafluor 488 or 
594 using Zenon labeling kit (Molecular Probes, Z25007, Z25102; Invitrogen). 
Primary antibodies, i.e. anti-ALDH1 (1:50; BD Biosciences, 61195; Franklin 
Lakes, NJ); CD44 (1:200; Abcam, ab51037) were added directly to the plate and 
incubated at 40C overnight. Orospheres were transferred to LabTek II 
Chambered Coverglass (Thermo Scientific) and mounted with Prolong Gold anti-
fade mounting medium with DAPI (Invitrogen). Confocal imaging was performed 
using Leica Inverted Confocal SP5X (Leica; Los Angeles, CA, USA). Post-
processing was done with NIH Image J software.  
Statistical analyses 
One-way ANOVA followed by appropriate post-hoc tests was performed 
using the SigmaStat 2.0 software (SPSS, Chicago, IL). Statistical significance 
was determined at P<0.05. 
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Results 
We show in Chapter III ALDH+CD44+ cells sorted from primary HNSCC 
exhibit self-renewal and are more tumorigenic than control ALDH-CD44- cells. 
Such features characterize the ALDH+CD44+ cells as putative head and neck 
cancer stem cells. Here, we describe the characterization and optimization of a 
method that was developed to propagate and to evaluate the stem cell properties 
of cells derived from primary head and neck tumors or from HNSCC cell lines. 
Single cell suspensions were prepared from freshly dissected human HNSCC, or 
from HNSCC cell lines. Cells were sorted for high/low ALDH activity (Aldefluor 
kit) and CD44 expression. A representative flow sorting of the head and neck 
cancer stem cells from a primary human HNSCC is shown in Figure 2.1, wherein 
the percentage of lineage-negative viable cancer stem cells (ALDH+CD44+) is 
0.97%, while the percentage of lineage-negative viable non-cancer stem cells 
(ALDH-CD44-) is 3.09%. After flow sorting, cells were cultured under low 
attachment conditions to form non-adherent spheres named orospheres. 
Orospheres were arbitrarily defined as non-adherent colonies of at least 25 cells. 
To generate these orospheres, we optimized conditions for HNSCC cells cultured 
either in ultra-low attachment plates or in soft agar 3-D matrices. While 
orospheres can be readily seen within 3 days in ultra-low attachment plates, it 
takes approximately 7 days to generate orospheres in soft agar (Figure 2.1B, 
2.1C). Notably, the orospheres shown here were generated either from cells 
sorted from a single primary human HNSCC (Figure 2.1B), or from a head and 
neck cancer cell line, i.e. UM-SCC-74A (Figure 2.1C). 
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To begin to understand the biology of the cells forming the orospheres, we 
cultured them for 3 days in ultra-low attachment plates and visualized the 
expression of the two stem cell markers used to sort the cells initially (ALDH1 
and CD44) by confocal microscopy (Figure 2.2A). To determine if the culture of 
putative cancer stem cells in low attachment represents a self-renewal method 
resulting in stem cell expansion, and not just an aggregation of stem-like cells, 
we seeded a single ALDH+CD44+ cell/well in 96-well ultra-low attachment plate 
and monitored its clonal expansion for 5 days (Figure 2.2B). We observed that a 
higher number of individual clones were formed by the putative cancer stem cells 
(ALDH+CD44+) when compared to control ALDH-CD44- cells (P<0.05). A clone 
was defined as a colony of at least 10 cells, starting from a single cell.  
To evaluate if the orosphere assay is a valid method for testing self-
renewal of head and neck cancer stem cells, we cultured orospheres generated 
from ALDH+CD44+ cells or control cells for 3 days under low attachment 
conditions. Then, the orospheres were mechanically dissociated and re-seeded 
as single cell suspension in new ultra-low attachment plates. This process was 
repeated serially to generate secondary and tertiary orospheres (Figure 2.2C). 
This experiment revealed two general trends: A) More orospheres were 
generated from the ALDH+CD44+ than from the control cells over time, 
demonstrating the self-renewal of the putative cancer stem cells. And, B) A 
progressive decrease in the overall number of orospheres was observed 
between the primary and the tertiary passage.  
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We wanted to ascertain that suspension culture in low attachment plates 
was the reason for the continued enrichment of cancer stem cells, and that 
ALDH+CD44+ cells do retain their stemness over time. We therefore cultured 
ALDH+CD44+ cells in regular attachment conditions or in ultra-low attachment 
plates. FACS analysis revealed the maintenance of an increased percentage of 
ALDH+CD44+ cells when culturing in ultra-low attachment conditions as 
compared to regular attachment plates (Figure 2.2D). The reverse experiment 
was performed to evaluate if the same putative head and neck cancer stem cells 
(ALDH+CD44+) would lose their stemness and differentiate when cultured in 
regular attachment plates. This analysis was performed by immunostaining for 
Cytokeratin 17 (an epithelial cell marker) and Involucrin (a differentiated cell 
marker) (Aragaki et al., 2010, Balasubramanian et al., 2007). We observed that 
on Day 0, the ALDH+CD44+ cells were more spherical and expressed high 
levels of Cytokeratin 17 and low levels of Involucrin (Figure 2.3A, 2.3B). By Day 
7, the ALDH+CD44+ cells became more elongated and reversed the expression 
levels of Cytokeratin 17 and Involucrin. 
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Discussion 
The orosphere assay is conceptually derived from suspension cultures 
developed to study normal or cancer stem cells from tissues such as the brain, 
breast, or prostate (Reynolds and Weiss, 1992, Dontu et al., 2003, Reynolds et 
al., 2006, Guzman-Ramirez et al., 2009). Pioneer work from Reynolds and Weiss 
demonstrated that cells dissected from the striatum of the adult mouse brain 
could be cultured as free-floating spheres and exhibited stem cell properties 
(Reynolds and Weiss, 1992, Reynolds et al., 2009). The Wicha laboratory 
characterized human mammary stem/progenitor cells from reduction 
mammoplasties based on their anchorage independence and survival in low 
attachment plates (Dontu et al., 2003). These seminal findings provided the 
conceptual framework for the development of sphere-based assays as a means 
to propagate cancer stem cells in an undifferentiated state in vitro. Here, we 
describe a method in which putative cancer stem cells are sorted from 
heterogeneous HNSCC primary tumors or from established HNSCC cell lines. 
These putative cancer stem cells differentiate under regular attachment 
conditions and generate heterogeneous tumor cell monolayers within a few days. 
On the other hand, the same cells cultured in low attachment conditions are 
capable of retaining stem-like cell properties (Figure 2.4). Notably, the method 
described here is clearly inspired by the existing protocols from other tumor 
types, but was optimized for use in head and neck tumor models. 
One of the critical challenges facing stem cell studies is the definition of 
markers that discriminate highly tumorigenic cells (cancer stem cells) from cells 
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that possess low tumorigenic potential. Mounting evidence suggests that stem 
cell markers are tumor-specific, and that CD44, CD133, and ALDH are emerging 
as useful markers in HNSCC. Seminal work from the Prince laboratory used 
CD44 expression as a marker for the identification of a sub-population of highly 
tumorigenic stem cells in primary HNSCC (Prince et al., 2007). More recently, it 
was shown that CD44+ cells sorted from a HNSCC cell line cultured in uncoated 
dishes formed tumor spheres that were resistant to chemotherapeutic drugs 
(Okomato et al., 2009). CD133, a transmembrane glycoprotein, is considered a 
putative marker for cancer stem cells in head and neck tumors. CD133 positive 
cells sorted from HNSCC cell lines or primary tumors showed enhanced clonality 
and tumorigenicity when compared to control cells (Zhou et al., 2007, Chiou et 
al., 2008, Zhang et al., 2010). Alternatively, ALDH activity, which was initially 
characterized as a useful stem cell marker in breast cancer (Ginestier et al., 
2007), was also validated in head and neck tumor models (Chen et al., 2009, 
Clay et al., 2010). Of note, since most markers are expressed in both normal and 
pathologic stem cells, it is plausible that the combination of markers may 
enhance one’s ability to identify cancer stem cells from complex primary tumor 
tissues. Indeed, it has been recently observed that the combination of ALDH 
activity and CD44 expression further discriminates a small sub-population (<3%) 
of cells in primary HNSCC that exhibit stem-like properties and are highly 
tumorigenic. 
As with most methods, the orosphere assay has its inherent limitations, as 
follows: A) The overall number of orospheres decreases upon serial passaging; 
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and B) The percentage of ALDH+CD44+ cells is higher in ultra-low attachment 
plates than in regular culture plates, but it decreases over time. Collectively, 
these findings suggest that there might be a certain degree of cell differentiation 
even in low attachment conditions in vitro. Although these limitations can be 
overcome by expanding cancer stem cells in vivo, (Prince et al., 2007) such 
strategy makes the process of propagating cells in an undifferentiated state labor 
and animal intensive, and expensive. While the “orosphere” assay has the 
advantages of being technically simple, reproducible, and relatively inexpensive, 
one must remain mindful of the limitations of the assay and interpret the results 
with caution. Ideally, the orosphere assay should be used for cell and molecular 
biology studies that are verified in appropriate animal models. 
We described here the protocols for generating orospheres in either soft 
agar 3-D matrices or in ultra-low attachment plates. Careful consideration should 
be given to the advantages and disadvantages of each method, before selecting 
the best approach for a specific experimental question. The soft agar method is 
more time consuming. One has to pre-coat the plate with a layer of agarose, wait 
for its gelification, apply a second layer containing both agarose and cells, wait 
again, and finally cover the 3-D gel with culture medium. Along the same lines, it 
takes about 7 days to generate orospheres in soft agar, while it takes only 3 days 
in ultra-low attachment plates. In addition, the soft agar approach does not allow 
for retrieval of the cells for mechanistic studies (e.g. flow cytometry, gene 
expression analyses) or for serial passage studies (e.g. to evaluate self-renewal 
properties). As a potential advantage though, the soft agar assay tends to be a 
44 
 
more rigorous testing of stem cell properties. We observed that non-cancer stem 
cells do not survive well under these conditions and do not readily form 
orospheres. On the other hand, the culture of undifferentiated cells in ultra-low 
attachment plates is simpler, since there is no need for coating and gelification 
steps. This culture condition is highly suitable for the retrieval of cells for serial 
passage or for mechanistic studies. Knowing the pros and cons of both strategies 
should direct the decision process towards selecting the soft agar or the ultra-low 
attachment approach. 
The field of cancer stem cell biology has attracted much attention in recent 
years due to the discovery that these cells may drive the progression of certain 
tumor types, including HNSCC. As such, the emergence of targeted therapy 
against cancer stem cells could have a significant impact on the survival of head 
and neck cancer patients. We believe that the development and characterization 
of methods to propagate and study the behavior of cancer stem cells in vitro may 
ultimately contribute to the discovery of mechanism-based therapies for head 
and neck squamous cell carcinoma. 
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Figure 2.1. In vitro propagation of putative head and neck cancer stem cells 
in orospheres. (A) Representative flow cytometry sorting of putative cancer 
stem cells from a primary human head and neck squamous cell carcinoma. 
Shortly after surgery, single cell suspensions were prepared by digestion of the 
tumor specimen with collagenase and hyaluronidase. Viable cells (P1) were 
isolated using 7AAD and are gated for positivity (after eliminating lineage cells) to 
ALDH (P5), using DEAB (ALDH inhibitor) as reference. ALDH-negative cells are 
found in P6. The cells were then gated against CD44 in sequence to select 
ALDH+CD44+Lin- (P7=0.97%) and ALDH-CD44-Lin- (P8=3.09%). (B,C) 
Representative photomicrographs of orospheres arising from ALDH+CD44+ and 
ALDH-CD44- cells sorted from a primary HNSCC and UM-SCC-74A and cultured 
either in ultra-low attachment plates (B) or in 3-D soft agar matrices (C).  
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Figure 2.2. Characterization of stem cell properties of orospheres. (A) 
Confocal microscopy of an orosphere generated from the UM-SCC-74B cell line 
and stained for the stem cell markers ALDH1 (green) and CD44 (red), along with 
nuclei staining with DAPI (blue). (B) Graph depicting the number of clones arising 
from one individual cancer stem cell (ALDH+CD44+) or non-cancer stem cell 
(ALDH-CD44-) per well of a 96-well ultra low attachment plate. (C) Graph 
depicting the number of orospheres generated from serial passage assays that 
evaluate self-renewal of putative cancer stem cells (ALDH+CD44+) or control 
cells (ALDH-CD44-). (D) Graph depicting the percentage of ALDH+CD44+ cells 
(FACS) over time when cultured in regular attachment or ultra-low attachment 
conditions. 
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Figure 2.3. Characterization of the differentiation of ALDH+CD44+ cells 
cultured in regular attachment plates. (A) Representative photomicrographs of 
Cytokeratin 17 and Involucrin immunostaining of ALDH+CD44+ cells cultured 
under regular attachment conditions for one week. (B) Graph depicting the 
percentage of cells cultured in regular attachment plates and that stained positive 
for Cytokeratin 17 or Involucrin over time.  
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Figure 2.4. Diagram illustrating the in vitro propagation of putative head 
and neck cancer stem cells using the orosphere assay. Single cell 
suspensions are prepared from head and neck squamous cell carcinomas and 
sorted for stem cell markers, such as ALDH and CD44. The putative cancer stem 
cells can be serially passaged and expanded in ultra-low attachment conditions 
using the orosphere assay. Alternatively, these cells can be differentiated when 
cultured in regular attachment conditions generating a heterogeneous cancer cell 
line. 
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CHAPTER III 
 
ENDOTHELIAL CELL-INITIATED SIGNALING PROMOTES THE SURVIVAL 
AND SELF-RENEWAL OF CANCER STEM CELLS 
 
 
Abstract 
 
Recent studies have demonstrated that cancer stem cells play an 
important role in the pathobiology of head and neck squamous cell carcinomas 
(HNSCC). However, little is known about functional interactions between head 
and neck cancer stem-like cells (CSC) and surrounding stromal cells. Here, we 
used Aldehyde Dehydrogenase activity and CD44 expression to sort putative 
stem cells from primary human HNSCC. Implantation of 1,000 CSC 
(ALDH+CD44+Lin-) led to tumors in 13 (out of 15) mice, while 10,000 non-cancer 
stem cells (NCSC; ALDH-CD44-Lin-) resulted in 2 tumors in 15 mice. These data 
demonstrated that ALDH and CD44 select a sub-population of cells that are 
highly tumorigenic. The ability to self-renew was confirmed by the observation 
that ALDH+CD44+Lin- cells sorted from human HNSCC formed more spheroids 
(orospheres) in 3-D agarose matrices or ultra-low attachment plates than controls 
and were serially passaged in vivo. We observed that approximately 80% of the 
CSC was located in close proximity (within 100-μm radius) of blood vessels in 
human tumors, suggesting the existence of perivascular niches in HNSCC. In 
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vitro studies demonstrated that endothelial cell-secreted factors promoted self-
renewal of CSC, as demonstrated by the up-regulation of Bmi-1 expression and 
the increase in the number of orospheres as compared to controls. Notably, 
selective ablation of tumor-associated endothelial cells stably transduced with a 
caspase-based artificial death switch (iCaspase-9) caused a marked reduction in 
the fraction of CSC in xenograft tumors. Collectively, these data demonstrated 
that endothelial cell-initiated signaling enhances the survival and self-renewal of 
head and neck cancer stem cells. 
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Introduction 
Head and neck squamous cell carcinoma (HNSCC) is the sixth most 
prevalent cancer type, accounting for more than 500,000 new cases each year in 
the world (Chin et al., 2006). The integration of platinum-based chemotherapy to 
the curative management of HNSCC resulted in an improvement in the control of 
local-regional disease and enhanced organ preservation (Forastiere, 2008). 
However, as the control of local-regional disease improved, the incidence of 
distant metastatic disease has risen (Gendel et al., 2003, Sano et al., 2007). As a 
result, the overall survival rate for patients with HNSCC has not improved 
significantly over the last 30 years and continues to be one of the lowest among 
the major cancer types. This clinical observation suggests that by creating a non-
favorable local environment for head and neck tumor cells with current therapies, 
these cells acquire a more aggressive phenotype leading to distant metastasis. 
Better understanding of the pathobiology of HNSCC is urgently needed for the 
development of more effective therapies. 
Cancer stem cells (CSC) constitute a sub-population of cells that are 
multi-potent, self-renewing, and capable of generating the entire heterogeneous 
population seen in tumors (Reya et al., 2001, Tu et al., 2009, Setoguchi et al., 
2004, Gupta et al., 2009). Cancer stem cells are believed to “drive” 
tumorigenesis of some cancer types, including breast and head and neck tumors 
(Prince et al., 2007, Cho et al., 2008, Shackleton et al., 2009). This implies that 
the successful growth of a metastasis of tumors that follow the cancer stem cell 
model requires that at least one cancer stem cell resists to therapy (Hill et al., 
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2009). Notably, cancer stem cells are slow-dividing cells that are capable of 
resisting to current therapies for cancer (Hermann et al., 2010).  
Stem cells and cancer stem cells are frequently found in unique 
microenvironments called the “niche” (Fuchs et al., 2004, Moore et al., 2006). 
Cell-to-cell interactions through direct contact or secreted factors support the 
survival and maintain the stemness of stem cells in cancer and in normal tissues 
(Lobo et al., 2007). Perivascular niches have been identified in neural stem cells 
(Shen et al., 2004, Sugiyama et al., 2006, Veeravagu et al., 2008) and neural 
tumors (Calabrese et al., 2007). However, it is not known if the stem cells of head 
and neck tumors are localized in close proximity to blood vessels and depend on 
interactions with the cellular components of vascular niches for their survival and 
stemness.  
Head and neck cancer stem cells were first identified using CD44 (Prince 
et al., 2007), a marker of stem cells in epithelial tumors (Al-Hajj et al., 2003, Li et 
al., 2007). Aldehyde Dehydrogenase (ALDH), an enzyme found to be highly 
active in stem cells of various origins (Corti et al., 2006, Ginestier et al., 2007, 
Huang et al., 2009), was recently used to identify stem cells in HNSCC (Chen et 
al., 2009). Here, we utilized ALDH1 and CD44 to identify a sub-population of 
cells that exhibit several properties of cancer stem cells, including self-renewal 
and capacity to regenerate heterogeneous tumors. Analysis of human HNSCC 
demonstrated that the majority of the cancer stem cells are located in close 
proximity to blood vessels. Using 3-D models in vitro, we showed that endothelial 
cell-secreted factors promote proliferation and self-renewal of HNCSC along with 
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increased expression levels of Bmi-1. Notably, selective ablation of tumor-
associated endothelial cells with a caspase-based artificial death switch resulted 
in a significant decrease in the number of cancer stem cells in vivo. Collectively, 
these data unveil the functional interdependency of cancer stem cells and 
vascular endothelial cells in head and neck tumors, and show proof-of-principle 
evidence that therapeutic targeting of tumor blood vessels reduces the number of 
CSC.  
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Materials and Methods 
Cell Culture 
Head and neck squamous cell carcinoma cell lines (UM-SCC-1, UM-SCC-
74A, UM-SCC-74B, UM-SCC-17A, UM-SCC-17B, UM-SCC-11B; gift from Dr. 
Carey, University of Michigan) were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM), 10% fetal bovine serum, 100 U/ml penicillin, 100 μg/ml 
streptomycin (Invitrogen; Grand Island, NY, USA) and human dermal 
microvascular endothelial cells (HDMEC; Cambrex, Walkersville, MD) in 
endothelial cell growth medium-2 (EGM2-MV; Lonza, Walkersville, MD, USA). 
FACS sorted cells were cultured in low glucose DMEM, 10% fetal bovine serum 
(Invitrogen) and 100 U/ml Penicillin-streptomycin (Invitrogen) or 100 U/ml 
Antibiotic Antimycotic Solution (AAA) (Sigma; St. Louis, MO, USA) in ultra-low 
attachment plates (Corning; New York, NY, USA). Conditioned Medium (CM) 
from HDMEC was collected in serum free DMEM from 24-hour cultures. HDMEC 
stably transduced with iCaspase-9 (HDMEC-iCaspase-9) were generated as 
described (Nör et al., 2002). The identity of all tumor cell lines was confirmed by 
genotyping at the University of Michigan DNA sequencing core facility. 
Head and neck cancer stem cell sorting  
Informed consent was obtained from patients undergoing surgery for 
removal of HNSCC. The tumors were obtained within 30 minutes post-surgery 
and transported in DMEM Low Glucose, 10%FBS, AAA to 40C immediately.  
Within 12 hours, the tumors were cut into small pieces and minced with a sterile 
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scalpel until they could pass through a 25 ml pipette tip. They were suspended in 
a 9:1 solution of DMEM-F12 (Hyclone, Waltham, MA) containing collagenase and 
hyaluronidase (Stem Cell Technologies; Vancouver, BC, Canada). The mixture 
was incubated at 370C for one hour and passed through a 10-ml pipette every 15 
minutes for mechanical dissociation. Cells were filtered through a 40-μm nylon 
mesh (BD Falcon; Franklin Lakes, NJ, USA), washed with low glucose DMEM 
containing 10% FBS, and centrifuged at 800 rpm for 5 minutes. Single cell 
suspensions obtained from primary specimens (as well as from cell lines or 
xenografts) were washed, counted, and re-suspended at 1×106cells/ml PBS. The 
Aldefluor kit (Stem Cell Technologies) was used to identify cells with high ALDH 
activity. Briefly, cells were suspended with activated Aldefluor substrate (BAA) or 
the negative control (DEAB, a specific ALDH inhibitor) for 45 minutes at 370C. 
Then, cells were exposed to anti-CD44 (clone G44-26BD; BD Pharmingen; 
Franklin Lakes, NJ, USA) and lineage markers (i.e. anti-CD2, CD3, CD10, CD16, 
CD18; BD Pharmingen). The sorted cells were cultured overnight and either 
implanted in mice or set up for in vitro experiments. Mouse cells were identified 
using anti-H2Kd antibody (BD Biosciences; Franklin Lakes, NJ, USA) and 
eliminated. Anti-CD31 (Biolegend; San Diego, CA, USA), anti-HA (Sigma) and 7-
Aminoactinomycin (7-AAD, BD Pharmingen) were used in selected experiments. 
Propidium iodide staining followed by flow cytometry was used for the 
identification of apoptotic cells (i.e. sub-G0/G1 cells). Here and throughout this 
manuscript, studies were done in triplicate specimens per condition and time 
point, and three experiments were performed to verify reproducibility of the data.  
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Confocal Microscopy   
Frozen sections were treated with peroxidase (Dako, CA) and the antigen 
retrieval solution (Dako) was used for 45 minutes at 90•C. The anti-ALDH1 (BD 
Biosciences), CD44 (Abcam, Cambridge, MA, USA) and Factor VIII 
(Neomarkers; Fremont, CA, USA) were pre-labeled with Alexafluor 488 or 594 as 
described using the Zenon labeling kit (Invitrogen) and confocal imaging was 
performed using Zeiss confocal (Carl Zeiss; Thornwood, NY, USA). Z–stacked 
images of 8 individual images were generated. The deconvolution was done 
using Autoquant (Media Cybernetics; Bethesda, MD, USA) and the 3-D 
reconstruction completed using the Imaris Software (Bitplane AG; Zurich, 
Switzerland).  
Colony formation assay and orospheres 
Colony formation assays were performed in 3-D suspension cultures, as 
described (Ginestier et al., 2007, Dontu et al., 2003). Orospheres (i.e. spheroids 
of HNSCC-derived cells) were generated from 5x103 cells cultured in triplicate in 
ultra-low attachment plates (Corning). Alternatively, cells were mixed with 0.3% 
agarose and layered on plates that were pre-coated with a layer of 0.6% 
agarose. Cells were maintained in low glucose DMEM containing or not 
conditioned medium from HDMEC at a ratio of 3:1. Orospheres generated in 
ultra-low attachment plates were mechanically dissociated into single cell 
suspensions and replated to generate secondary and tertiary cultures.  
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SCID mouse model of human tumor angiogenesis  
Xenograft tumors vascularized with functional human microvessels were 
generated in severe combined immunodeficient (SCID) mice (CB 17 SCID, 
Taconic; Germantown, NY, USA), as described (Nör et al., 2001). Briefly, 1,000 
CSC (ALDH+CD44+Lin-) or 10,000 NCSC (ALDH-CD44-Lin-) were seeded with 
HDMEC for a total of 1x106 cells in poly-(L-lactic) acid (PLLA; Medisorb, Nicosia, 
Cyprus) biodegradable scaffolds. Bilateral scaffolds were implanted 
subcutaneously in the dorsum of each mouse. Mice were monitored daily for 
tumor growth for 6 months or until the volume of the tumor reached 0.85 cm3. 
Alternatively, mice received scaffolds containing 9.99x105 HDMEC-iCaspase-9 
and 1x103 CSC, or controls. 24 days after transplantation of the scaffolds, mice 
received daily intra-peritoneal injections of 2 mg/kg AP20187 (ARIAD; 
Cambridge, MA, USA) for 4 days to activate iCaspase-9 and selectively ablate 
tumor blood vessels, as described (Nor et al., 2002).  
Immunohistochemistry 
Immunostaining for ALDH1 (BD Biosciences, 61195, 1:100), Factor VIII 
(Neomarkers, 1:500), pancytokeratin (Dako, clone A E1/E3 3515; 1:500) was 
performed, and DAB or AEC substrate was used to develop the color. Factor VIII 
and ALDH1 quantification was done in 6 random areas of 6 sections in 8 
individual tumors in a 400X magnification. The ALDH1-positive cells of all 
sections were added and expressed as a percentage for each patient and the 
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average of the 8 patients was calculated. Isotype matched immunoglobulins were 
used as negative controls.  
Proliferation Assays  
For proliferation experiments, 2x103 cells (ALDH+CD44+ and ALDH-
CD44-) were cultured in 24-well ultra-low attachment plates and treated with 
control or endothelial cell (HDMEC) conditioned medium every 2 days for a 
week. WST-1 (Roche) reagent was added, incubated for 2 hours and read off the 
spectrophotometer (Genious; Tecan). Results were normalized against initial 
plating density. Experiments were done in triplicate wells per condition, and each 
graph is representative of three independent experiments.  
Western Blots  
40,000 ALDH+CD44+ or ALDH-CD44- cells were plated in 6-well ultra-low 
attachment plates, serum starved overnight, and treated with endothelial cell 
conditioned medium (CM) for 0-24 hours. Western blots were performed with 
rabbit anti-human Bmi-1 (Millipore, 05-637) or mouse anti-human caspase-9 
(Cayman Laboratory).  
Generation of HDMEC-icaspase9-HA cells 
These cells were generated, as described (Nör et al., 2002).  Briefly, 
HDMEC was transduced with either iCaspase-9 (HA tagged) or LXSN (empty 
retroviral vector control) and selected for G418 for a minimum of 2 weeks. 
Expression of iCaspase-9 was checked with Western Blots as described above.  
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Statistical Analyses 
T-test or one-way ANOVA followed by post-hoc analyses was performed 
using the SigmaStat 2.0 software (SPSS, Chicago, IL). Statistical significance 
was determined at P < 0.001 (unless otherwise specified). 
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Results 
ALDH+CD44+Lin- cells retrieved from primary head and neck squamous 
cell carcinomas are highly tumorigenic. CD44 was used as the marker for 
stem cells in the study that demonstrated the existence of stem cells in head and 
neck squamous cell carcinomas (Prince et al., 2007). However, a relatively large 
proportion of cells were found to be positive for CD44 in that study. Here, we 
tested the combined use of ALDH activity and CD44 expression in different 
combinations to identify cells that have a cancer stem-like phenotype (Figure 
3.1A) and ALDH+CD44+ cells were more stem like. Confocal microscopy of 
ALDH-positive cells (green) was seen to co-localize with some of the CD44 (red) 
cells in a primary HNSCC patient (Figure 3.1 B). The efficacy of tumor take was 
compared when putative CSC cells (ALDH+CD44+Lin-) or non-CSC cells 
(ALDH-CD44-Lin-) were implanted in immuno-deficient mice (Figure 3.2A). 
Single cell suspensions were prepared from 4 different patients with primary 
human head and neck squamous cell carcinomas immediately after surgical 
resection (Table 3.1). Viable cells were selected with 7-AAD (P1) and then gated 
in sequence for ALDH activity and CD44 expression, after elimination of lineage 
(Lin) cells (Figure. 3.2A). We observed that 1.78% of the cells were 
ALDH+CD44+Lin- (putative CSC) and 8.7% were ALDH-CD44-Lin- (NCSC) in a 
representative tumor (HN 10) (Figure. 3.2A, Table 3.1). To evaluate the 
tumorigenicity of these cells, 1,000 ALDH+CD44+Lin- or 10,000 ALDH-CD44-
Lin- (10-fold more cells) were co-implanted with human endothelial cells to 
generate human xenograft tumors vascularized with human blood vessels in 
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immuno-deficient mice, as described (Nor et al., 2001). 13/15 implants generated 
palpable tumors (tumors that are bigger than the scaffold volume), in the 
ALDH+CD44+Lin- group as compared to 2/15 of the ALDH-CD44-Lin- group, 
demonstrating that the combination of ALDH and CD44 allowed for selection of a 
highly tumorigenic sub-population of cells (Figure 3.2B). To evaluate their 
capacity of self-renewal, viable tumor xenografts were retrieved at six months or 
when their volume reached 850 mm3, processed into single cell suspensions, 
and serially transplanted to other mice. All implants containing ALDH+CD44+Lin- 
cells generated secondary tumors, whereas none of the implants containing 
ALDH-CD44-Lin- cells generated tumors (Figure 3.2B). The tumor volumes of the 
primary and secondary xenografts generated with ALDH+CD44+Lin- cells was 
higher than with the ALDH-CD44-Lin- cells (p < 0.001) at the end of the 
experimental period (Figure 3.2C). Notably, the fraction of the putative CSC 
(ALDH+CD44+Lin-) in the primary and secondary xenografts remained low and 
comparable to the fraction of these cells in the primary human tumors (Figure 
3.2D). This observation along with the fact that the primary xenografts on 
digestion yielded both ALDH+CD44+ cells and ALDH-CD44- cells as well as the 
heterogeneity of tumors and being capable of being serially implanted into 
generating secondary xenografts indicated that the ALDH+CD44+Lin- cells 
exhibit features of multipotency.  
Xenografts generated with ALDH+CD44+Lin- cells resemble the primary 
tumors. The histological organization of the primary and secondary xenograft 
tumors generated from the ALDH+CD44+Lin- cells was comparable to the 
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primary tumor from which these cells were retrieved (Figure 3.3A). In contrast, 
most of the implants seeded with ALDH-CD44-Lin- did not generate tumors. And, 
in the few instances (2 out of 15 implants) that tumors were generated from these 
cells, they were structurally disorganized and had smaller tumor islands as 
compared to xenografts generated from ALDH+CD44+Lin- cells (Figure 3.3A). 
The epithelial origin of the tumor xenografts was confirmed by positive 
immunostaining for pancytokeratin (Figure 3.3B). Analysis of the localization of 
the stem-like cells (ALDH-positive; arrows) within these xenografts revealed that 
the majority of these cells were found within 100-µm of blood vessels (Figure 
3.3C,D). This observation led us to a more in depth analysis of the localization of 
stem-like cells in primary tumors.  
Head and neck cancer stem-like cells exhibit perivascular localization. In 
oral mucosa, the small sub-population of ALDH-positive cells was found primarily 
in the basal layer of the squamous epithelium (Figure 3.4A), the expected 
localization of stem cells in this tissue. In HNSCC, the ALDH-positive cells were 
seen in tumor islands, in close proximity to blood vessels (Figure 3.4A). To 
assess the relative percentage of potential stem cells in oral mucosa and 
HNSCC, we prepared single cell suspensions and sorted them for ALDH and 
CD44. The average proportion of ALDH+CD44+ was 0.2% (0.2%, 0.43%, 
0.316%) average in oral mucosa and 2.62% in HNSCC (2.86%, 3.15%, 1.85%) 
(from 3 different patients). Confocal microscopy and 3-D image reconstruction 
were used to evaluate the spatial relationship between ALDH-positive cells and 
blood vessels in 8 patients with HNSCC (Figure 3.4B-D). An area with 100-μm 
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radius around each blood vessel was selected as representative of the 
“perivascular” area, since this is the approximate area of diffusion of oxygen and 
nutrients around vessels (Janssen et al., 2002). We observed that the majority of 
the CSC (i.e. approximately 80%) was found in the perivascular area in human 
HNSCC (Figure 3.4D).  
Endothelial cell-derived growth factor milieu promotes proliferation, 
survival, and self-renewal of HNCSC. To understand whether endothelial cell-
secreted factors have a direct functional effect on HNCSC, we studied the effect 
of endothelial cell conditioned medium on proliferation, survival and self-renewal 
of ALDH+CD44+ selected from a panel of established head and neck tumor cell 
lines in vitro. The proliferation of both, ALDH+CD44+ and ALDH-CD44- cells 
cultured in low attachment conditions was enhanced by exposure to endothelial 
cell conditioned medium (Figure 3.5A). The increase in cell numbers may also be 
attributed to an enhancement in survival mediated by the endothelial cell-derived 
factors (Figure 3.5B).  
Due to the difficulty in obtaining primary HNSCC, we performed a series of 
in vitro experiments using an established panel of cell lines (Table 3.2). To 
evaluate the self-renewal potential of CSC, we plated them in agarose and 
observed the formation of colonies in a three-dimensional culture condition 
(Figure 3.8). We observed the formation of sphere-like colonies developed from 
single cells (Figure 3.6A and B), using a method inspired by the work on 
“mammospheres” (Dontu et al., 2003). These colonies derived from head and 
neck tumor stem-like cells were named “orospheres”. The number of colonies 
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generated from ALDH+CD44+ cells was greater than ALDH-CD44- cells (P < 
0.001), using cells sorted from three established HNSCC cell lines, i.e. UM-SCC-
17A, UM-SCC-1 and UM-SCC-74A (Figure 3.6A). To evaluate the behavior of 
these cells over time, the orospheres were dissociated and passed twice. While 
the overall number of orospheres decreased over time, the ALDH+CD44+ group 
persistently presented higher number of orospheres than the control group over 
three serial passages in vitro (Figure 3.6B). Notably, ALDH+CD44+ cells strongly 
express the marker of self-renewal Bmi-1, as compared to control ALDH-CD44- 
cells (Figure 3.6C). In the same experiment, we observed that endothelial-cell 
secreted factors enhances expression of Bmi-1 in ALDH+CD44+ cells over time, 
indicating an inductive effect of these factors on the self-renewal properties of the 
CSC (Figure 3.6C).  
          To understand the effect of endothelial cells on self-renewal of stem cells, 
and to ensure comparability of these established cell lines with primary samples, 
we isolated ALDH+CD44+Lin- cells from primary HNSCC, and performed the 
orosphere assay with primary cells. A 3-fold increase in the number of 
orospheres was observed in the group treated with endothelial cell conditioned 
medium (P < 0.001), as compared to untreated controls (Figure 3.7A). These 
results were verified in experiments performed with 6 additional head and neck 
tumor cell lines (Figure 3.7B; Figure 3.8). Notably, the inductive effect of 
endothelial cell-secreted factors on the number of orospheres generated from 
ALDH+CD44+ cells was maintained during 3 serial passages in vitro (Figure 
3.7C).  
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Selective ablation of blood vessels reduces the proportion of cancer stem 
cells. A critical question that remained unanswered was if the effects of 
endothelial cells on the survival and self-renewal of head and neck tumor stem 
cells was also observable in vivo. To address this question, we utilized two 
complementary approaches. Firstly, serial dilutions (i.e. 1000, 100, 10 and 1 
ALDH+CD44+Lin- cells;) from a primary HNSCC, were prepared, seeded in the 
scaffolds with or without HDMEC, and implanted in the subcutaneous space of 
immunodeficient mice. Co-implantation of endothelial cells and CSC resulted in 
larger tumors than implantation of CSC by themselves (Figure 3.10). Secondly, 
endothelial cells were stably transduced with a caspase-based artificial death 
switch (iCaspase-9) (Figure 3.9A). This unique approach allows for selective 
elimination of endothelial cells transduced with iCaspase-9 upon activation by the 
dimerizer drug AP20187 and ablation of tumor vasculature in vivo (Nor et al., 
2002, Dong et al., 2007). Here, we showed that treatment with AP20187 induces 
apoptosis of HDMEC-iCaspase-9, but not untransduced cells (i.e. ALDH+CD44+ 
cells) (Figure 3.9B). As expected, AP20187-induced apoptosis of the iCaspase-
9-transduced endothelial cells resulted in a significant reduction in the 
microvessel density of tumors retrieved from mice injected with AP20187, as 
compared to vehicle-treated controls (Figure 3.9C). Notably, the proportion of 
ALDH+CD44+Lin- cells within the xenograft tumors was significantly reduced 
when endothelial cells were selectively ablated by activation of iCaspase-9, as 
compared to vehicle-treated controls (Figure 3.9D).  
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Discussion 
The poor survival and high recurrence rates in patients with HNSCC 
demand a re-assessment of the pathobiology of these cancers. Here, we showed 
that head and neck cancer stem cells reside in perivascular niches. Notably, we 
observed that endothelial cell-secreted factors have a major impact on the self-
renewal and survival of cancer stem cells. These data suggest that therapeutic 
targeting of the tumor endothelium may reduce the rate of head and neck tumor 
recurrence and metastasis by decreasing the proportion of cancer stem cells.  
Prince and colleagues (2007) reported that CD44+ cells from primary 
HNSCC exhibit a cancer stem-cell phenotype, and are capable of initiating 
tumors at low numbers (Prince et  al., 2007). ALDH1 has been recently described 
as a putative marker for CSC in head and neck tumors (Chen et  al., 2009). Here, 
we demonstrate that the combination of ALDH1 and CD44 selects a sub-
population of cells with properties of cancer stem cells than if used as single 
markers. One thousand ALDH+CD44+ cells were capable of initiating tumors 
much more efficiently than 10,000 ALDH-CD44- cells. ALDH+CD44+ cells could 
also be transplanted serially and generated secondary xenografts, evidencing the 
self-renewal nature of these cells. It is noteworthy that although control ALDH-
CD44- cells formed a few primary xenografts (2 out of 15), we did not observe 
any tumor being formed from the serial transplantation experiments with these 
cells. The two tumors generated from ALDH-CD44- cells could be due to the 
existence of a few progenitor cells with the capability of tumor initiation or 
possible inaccuracy of FACS sorting. Moreover, the histology of the xenografts 
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obtained from the ALDH+CD44+ cells resembled that of primary tumors. These 
findings confirmed that the xenografts were of human epithelial origin and 
supported the hypothesis that ALDH+CD44+ cells have a behavior that is 
consistent with the behavior of cancer stem cells.  
We observed that ALDH-positive cells are found primarily in the basal 
layer of the oral epithelium, where stem cells of the skin have been traditionally 
found (Fuchs et al., 2004, Blanpain et al., 2004). In contrast, in the HNSCC the 
ALDH-positive cells have a more disperse localization within the tumor 
microenvironment. Of note, the ALDH-positive cells were consistently localized 
within close proximity of blood vessels. The close association of cancer stem 
cells and blood vessels has earlier been documented in the nervous system and 
that these vascular niches helped in the maintenance of stem cells and cancer 
stem cells (Shen et al., 2004, Calabrese et al., 2007, Shen et al., 2008). 
However, such association has not been reported yet for head and neck tumors.  
The cancer stem cells are believed to escape current therapies like 
radiation and chemotherapy and possibly lead to recurrences in various cancers. 
Thereby, identifying and targeting cancer stem cells or their niches might be a 
novel therapeutic strategy in the clinic (Okamoto et al., 2009). However, to be 
able to target the cancer stem cells or their niches, we have to understand its 
pathobiology, identify their niches and their effects on the cancer stem cells. 
Endothelial cells have been implicated in the self-renewal and survival of neural 
cancer stem cells (Calabrese et al., 2007). Studies in hematopoietic stem cells 
suggest that the vascular niche can promote cell survival signals (Sugiyama et 
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al., 2006), which could make them resistant to chemotherapies. Other groups 
have studied the effects of endothelial cell survival and self-renewal on cancer 
stem cells in neural tumors (Calabrese et al., 2007, Folkins et al., 2007). Anti-
angiogenic agents (e.g. bevacizumab) have been shown to mediate depletion in 
the cancer stem cells in models of gliomas and medulloblastomas. Here, we 
used a unique experimental approach to selectively eliminate tumor-associated 
endothelial cells and evaluate the effect on the stem cell compartment. Unlike 
previous experimental strategies that were based on anti-angiogenic drugs, the 
approach used here eliminates the risk of a direct effect of the drug on the 
viability or stemness of the tumor stem cells. In our strategy, in 4 days, we saw a 
significant reduction in the CSCs%, suggesting that the endothelial cells play a 
direct role in the survival of the cancer stem cells. Our experiments revealed that 
selective ablation of tumor-associated blood vessels are sufficient to decrease 
the proportion of head and neck tumor stem cells in vivo.  
Our work demonstrates that endothelial cells initiate signaling events that 
enhance the survival and self-renewal of stem cells in head and neck tumors. In 
addition, the data presented here supports the concept that head and neck 
cancer indeed follows the cancer stem cell hypothesis, since implantation of few 
cells consistently gives rise to tumors that can be serially passaged in vivo. 
Collectively, these data suggest that therapeutic strategies that include anti-
angiogenic agents might have the benefit of reducing the proportion of cancer 
stem cells in head and neck tumors. These results might translate into lower 
recurrence rates and better survival of head and neck cancer patients. 
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Figure 3.1.  ALDH+CD44+ cells have a purer sub-population of cells 
exhibiting cancer stem like cells. (A), Graph depicting the quantification of the 
relative number of colonies/well arising from ALDH+CD44+, ALDH+CD44-, 
ALDH-CD44+ and ALDH-CD44- cells treated with endothelial cell conditioned 
medium (CM) or unconditioned medium for one week.  (B), Confocal microscopy 
of human HNSCC immunostained for ALDH1 (green), CD44 (red) and DAPI for 
the nuclei. The overlay image shows the predominant co-localization of the 
ALDH positive (green) and CD44-positive cells  
A 
B 
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Table 3.1.  Table depicting the characteristics of the HNSCC. The patients in 
Figure 1 and their relative CSC% (ALDH+CD44+) and NCSC% (ALDH-CD44-). 
The table also illustrates the individual primary and secondary xenografts 
generated out of the total number of implants from each of the HNSCC by 
implanting 1,000 CSC or 10, 000 NCSC. N/A indicates no implantation was done 
due to lack of cells post-sorting. 
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Figure 3.2. Combination of ALDH and CD44 selects highly tumorigenic 
cells. (A), Schematic representation of the approach for testing tumorigenic 
potential of cells. ALDH+CD44+Lin- cells were isolated from HNSCC and serially 
transplanted into immunodeficient mice to generate primary and secondary 
xenografts. Representative flow cytometry: Viable cells (P1) are isolated from a 
head and neck squamous cell patient (HN 10) using 7AAD and are gated for 
positivity to ALDH (P6), using DEAB (ALDH inhibitor). ALDH-negative cells in P5. 
ALDH+CD44+Lin- (P8=1.78%) and ALDH-CD44-Lin- (P7=8.7%). (B), Graph 
depicting the volume of primary and secondary xenografts. (C), Graph depicting 
the xenograft tumors (primary and secondary) obtained by implantation of 1,000 
ALDH+CD44+Lin- or 10,000 ALDH-CD44-Lin- cells selected from human 
HNSCC (n=15). (D), Graph depicting the percentage of putative head and neck 
cancer stem cells (ALDH+CD44+Lin-) in primary tumors, primary and secondary 
xenografts 
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Figure 3.3. Head and neck cancer stem-like cells generate xenografts with 
histological features that closely resemble those primary tumors. (A), 
Photomicrographs of a representative primary tumor (HN10), and respective 
primary and secondary xenograft originated by the transplantation of 
ALDH+CD44+Lin- cells (HE staining). Control tissues generated by the 
implantation of ALDH-CD44-Lin- cells. (B), Expression of pancytokeratin in the 
primary tumor, respective primary and secondary xenograft, and IgG control 
group. (C), Representative photomicrographs of ALDH1 immunostaining of 
primary tumors and respective xenografts (Arrows depict ALDH1 positive cells 
present in spatial relationship to blood vessels. (D), Graph depicting the 
percentage of ALDH1 positive cells found within a 100-μm radius of blood 
vessels in the primary tumors and xenografts generated by the transplantation of 
ALDH+CD44+Lin- cells. 
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Figure 3.4. Head and neck cancer stem-like cells are localized in close 
proximity to blood vessels. (A), Representative photomicrographs of tissue 
sections stained with HE or immunostained for ALDH1 in human HNSCC and 
control oral mucosa (identified by arrows). (B), Confocal microscopy of human 
HNSCC immunostained for ALDH1 (green) and Factor VIII (red) for localization 
of blood vessels. The overlay image shows the perivascular localization of the 
ALDH-positive cells. (C), 3-D reconstruction of the image in B,d showing the 
proximity between ALDH-positive cells (green) and blood vessels (red). (D), 
Graph depicting ALDH-positive cells found within 100-μm radius of blood vessels 
in 6 random areas of 6 different sections taken together and expressed as a 
percentage for each individual patient and the average of 8 individual HNSCC 
patients are shown. 
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Figure 3.5. Endothelial cell Conditioned Medium promotes proliferation and 
prevents apoptosis of head and neck cancer stem cells. (A), Graph depicting 
the effect of endothelial cell conditioned medium (EC CM) on the proliferation of 
ALDH+CD44+ and ALDH-CD44- cells. (B), Graph depicting the percentage of 
apoptotic cells when ALDH+CD44+ or ALDH-CD44- cells are exposed to the 
conditioned medium from endothelial cells (EC CM) for one week. 
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Table 3.2 Table showing the various cell lines used in the study, their origin 
and their relative cancer stem cells. CSC% (ALDH+CD44+) and NCSC% 
(ALDH-CD44-). 
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Figure 3.6. ALDH and CD44 select for a sub-population of cells that exhibit 
self-renewal properties in vitro. (A), Representative photomicrographs of 
colonies (orospheres) arising from ALDH+CD44+ and ALDH-CD44- cells sorted 
from UM-SCC-74A and grown in 3-D agarose matrices. Graph depicts the 
quantification of the number of colonies arising from cancer stem-like cells (CSC; 
ALDH+CD44+) or non-cancer stem cells (NCSC; ALDH-CD44-) sorted from 
three HNSCC cell lines (UM-SCC-17A, UM-SCC-1, UM-SCC-74A) and cultured 
in 3-D agarose matrices. (B), Representative photomicrographs of orospheres 
arising from ALDH+CD44+ and ALDH-CD44- cells sorted from UM-SCC-74A and 
grown in ultra-low attachment plates. Graph depicting the number of orospheres 
from serial passage assays that evaluate self-renewal of CSC (ALDH+CD44+) 
and NCSC (ALDH-CD44-) cells in vitro. Asterisk depicts P < 0.001. (C), Western 
blot depicting the expression of Bmi-1 in CSC (ALDH+CD44+) and NCSC 
(ALDH-CD44-) cells treated with endothelial cell conditioned medium (EC CM). 
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Figure 3.7. Endothelial cell-derived factors promote proliferation and self-
renewal of head and neck cancer stem-like cells. (A), Photomicrographs of 
representative colonies arising from ALDH+CD44+Lin- cells sorted from a human 
HNSCC and grown in 3-D Agarose matrices. Cells were treated with endothelial 
cell conditioned medium (CM) or unconditioned control medium (CT) for one 
week. Asterisk depicts P < 0.001. (B), Time course experiment depicting the 
number of orospheres arising from CSC (ALDH+CD44+) and NCSC (ALDH-
CD44-) cells treated or not with endothelial cell conditioned medium (CM) over a 
period of 4 weeks. (C), Photomicrographs of representative colonies arising from 
ALDH+CD44+Lin- cells sorted from UM-SCC-74A cells and cultured in ultra-low 
attachment plates. Cells were treated with endothelial cell conditioned medium 
(CM) or unconditioned control medium (CT). Graph depicting primary, secondary 
and tertiary orospheres arising from ALDH+CD44+ treated with endothelial cell 
conditioned medium (CM) or control medium (CT). Asterisk depicts P < 0.05. 
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Figure 3.8. Endothelial Cell Conditioned Medium promotes self-renewal of 
head and neck cancer stem-like cells. (A), Schematic drawing of the colony 
formation assay in 3-D agarose matrices. (B), Graphs depicting the quantification 
of the relative number of colonies/well arising from ALDH+CD44+ (CSC) and 
ALDH-CD44- (NCSC) cells treated with endothelial cell conditioned medium 
(CM) or unconditioned medium for four weeks. Four head and neck squamous 
cell carcinoma cell lines were used to verify the reproducibility of results, i.e. UM-
SCC-11B, UM-SCC-1, UM-SCC-17A and UM-SCC-17B. 
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Figure 3.9. Selective ablation of tumor-associated endothelial cells 
decreases the number of head and neck cancer stem-like cells. (A), Western 
blot showing 4 clones of HDMEC stably transduced with the caspase-based 
artificial death switch iCaspase9. Clone “d” was selected for remaining 
experiments depicted in this figure. (B), Graph depicting the proportion of 
apoptotic cells when HDMEC-iCaspase-9 or ALDH+CD44+ cells are exposed to 
the dimerizer drug AP20187.  (C), Graph depicting the tumor microvessel density 
of xenografts generated by the co-transplantation of HDMEC-iCaspase-9 and 
ALDH+CD44+ cells in immunodeficient mice. Mice were injected with AP20187 
to activate Caspase-9 and selectively eliminate the xenograft tumor blood 
vessels. (D), Graph depicting the percentage of ALDH+CD44+ cells in the 
AP20187-treated tumors compared to vehicle treated controls. Asterisk depicts P 
< 0.005. 
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Figure 3.10. Endothelial cells enhance the tumorigenic potential of head 
and neck cancer stem cells. Graph depicting the volume of tumor generated by 
the transplantation of 1-1,000 head and neck cancer stem cells 
(ALDH+CD44+Lin-) from a primary HNSCC (HN 18) with or without endothelial 
cells (HDMEC). Asterisk depicts P < 0.001. 
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CHAPTER IV 
 
ENDOTHELIAL CELL-INITIATED IL-6 SIGNALING  
PROMOTES SELF-RENEWAL, SURVIVAL AND TUMOR INITIATION  
OF CANCER STEM CELLS 
 
 
Abstract 
 
Head and neck squamous cell carcinomas display cellular heterogeneity 
with ALDH+CD44+ cells exhibiting cancer stem-like properties. ALDH+CD44+ 
cells were recently found to exist in vascular niches and that endothelial cells 
promoted their self-renewal and survival. However, molecular mechanisms 
underlying the endothelial cell-cancer stem interaction have been largely 
unknown. Here, we report that endothelial cells expressed higher IL-6 levels than 
the adjacent tumor cells in primary head and neck squamous cell carcinomas 
(HNSCC), and observed that the cancer stem cells preferentially express IL-6R 
and phosphorylated-STAT3. Targeting endothelial cell secreted IL-6 by either 
neutralizing antibody or gene silencing (using shRNA) strategies decreased the 
sphere forming capacity and the invasive potential of the ALDH+CD44+ cells. 
Endothelial cells stably expressing shRNA-IL-6 decreased tumorigenicity and 
tumor growth in vivo. Tumor initiation and growth was significantly decreased in 
the absence of IL-6 in the tumor micro-environment as seen in transgenic mouse 
models. Interrupting IL-6 signaling by means of a humanized IL-6R antibody 
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resulted in delayed tumor initiation and decreased the survival of head and neck 
cancer stem cells in vivo. Collectively, these data indicate that IL-6/IL-6R 
represents a potential therapeutic target for head and neck cancer stem cells.  
93 
 
Introduction 
Head and neck squamous cell carcinomas, like many other human 
carcinomas may be driven by a population of cells called the cancer stem cells; 
possessing stem cell properties of self-renewal and differentiation (Prince et al., 
2007, Chen et al., 2009, Hermann et al., 2010). There is evidence in recent years 
that these cancer stem cells could possibly participate in the processes that lead 
to resistance to therapy and the establishment of distant metastases (Kakarala et 
al., 2008, Chen et al., 2010) resulting in poor patient survival (Al-Swiahb et al., 
2010). Recently, CD44+ cells were shown to have increased tumorigenicity and 
self-renewal properties in HNSCC (Prince et al., 2007). Aldehyde 
Dehydrogenase I, a cancer stem cell marker identified in various tissues of origin 
like the brain, breast and colon (Corti et al., 2006, Ginestier et al., 2007, Huang et 
al., 2009), was recently used to identify stem cells in HNSCC (Chen et al., 2009, 
Krishnamurthy et al., 2010). These ALDH+CD44+ cells expressed the stem cell 
properties of self-renewal and increased tumorigenicity (Krishnamurthy et al., 
2010) and were found to be radio-resistant (Chen et al., 2010).  
Stem cells and cancer stem cells of various tissues have been found to 
reside in the basal layer of the tissues (Tumbar et al., 2004, Kopan et al., 1989) 
and have been found to be dependent on the tumor microenvironment for their 
growth and survival (Lobo et al., 2007, Polyak et al., 2009, Parmar et al., 2011). 
Recently, peri-vascular niches have been identified in neural stem cells (Shen et 
al., 2004, Sugiyama et al., 2006, Veeravagu et al., 2008) and neural tumors 
(Calabrese et al., 2007). In HNSCC, we identified a peri-vascular niche and 
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demonstrated that endothelial cell secreted factors promote survival and self-
renewal of head and neck cancer stem cells in vitro and in vivo (Krishnamurthy et 
al., 2010). Anti-angiogenic therapy thus was an attractive cancer stem-cell based 
therapy for head and neck cancers. However, recent evidence suggested that 
anti-angiogenic therapy (especially anti-VEGF based therapy) could lead to 
higher numbers of tumor cell infiltration thereby causing a malignant progression 
of tumors and increased metastasis, (Paez-Ribes et al., 2009; Keunen et al., 
2011). This therefore, suggested a more targeted study needs to be done on 
possible molecular pathways contributing to cancer stem cell survival and self-
renewal. 
The inflammatory cytokine, Interleukin-6 (IL-6) has been found to play a 
pivotal role in the mediation of interaction in cancer stem cells and their micro-
environment in numerous tissues including the breast and brain (Sansone et al., 
2007, Wang et al., 2009, Liu et al., 2011, Marotta et al., 2011). The IL-6 ligand 
receptors, IL-6R and gp130, have been found to have aberrant expression levels 
in glial cancer stem cells (Wang et al., 2009). In tumors like lung 
adenocarcinomas, glioblastomas and head and neck cancers, IL-6 expression 
levels and its downstream activation target of signal transducer and activator of 
transcription 3 (STAT3) has been found to be highly expressed (Gao et al., 2007, 
Seethala et al., 2008). Moreover, increased serum IL-6 levels have been co-
related with tumor recurrences and poorer patient prognosis in HNSCC in a 
longitudinal cohort study (Duffy et al., 2008). Additionally, STAT3 has been found 
to be constitutively active in HNSCC and inhibition of STAT3 by various inhibitors 
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like Erlotinib or Cucurbitacin I has been found to decrease tumorigenesis in 
squamous cell carcinomas (Leeman-Neill et al., 2011, Chen et al., 2010). 
However, the specific role of IL-6 signaling is unknown in head and neck cancer 
stem cells.  
In this study, we unveil a paracrine pathway (IL-6-IL6R-STAT3 pathway) 
for the head and neck cancer stem cells via their niche (the perivascular niche) 
which promotes self-renewal and tumor initiation in HNSCC. Using Laser capture 
microdissection technique, we establish the relative IL-6 levels in the tumor 
endothelial cells and tumor cells in HNSCC primary patients. We demonstrate 
using neutralizing antibodies and shRNA strategies that endothelial cell-initiated 
IL-6 promotes self-renewal and invasion in vitro and tumor initiation in vivo and 
corroborate this using IL6-/- mice studies. Finally, using a humanized anti-IL6R 
antibody, we propose a novel molecular targeting therapy for head and neck 
cancer stem cells as an adjunct with current therapy to potentially delay or 
prevent recurrences in HNSCC. 
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Materials and Methods 
 Cell Culture  
Head and neck squamous cell carcinoma cell lines (UM-SCC-74A, UM-
SCC-74B, UM-SCC-17B; gift from Dr. Carey, University of Michigan) were 
cultured in Dulbecco’s Modified Eagle Medium (DMEM), 10% fetal bovine serum, 
100 U/ml penicillin, 100 μg/ml streptomycin (Invitrogen; Grand Island, NY, USA) 
and human dermal micro vascular endothelial cells (HDMEC; Cambrex, 
Walkersville, MD) in endothelial cell growth medium-2 (EGM2-MV; Cambrex). 
The identity of tumor cell lines was confirmed by genotyping at the University of 
Michigan DNA sequencing core facility. FACS sorted cells were cultured in low 
glucose DMEM, 10% fetal bovine serum (Gibco, Invitrogen) and 100 U/ml 
Penicillin-streptomycin (Invitrogen) or 100 U/ml Antibiotic Antimycotic Solution 
(Sigma) in ultra-low attachment plates (Corning Inc; New York, NY, USA). 
Conditioned Medium (CM) from HDMEC was collected in serum free DMEM from 
24-hour cultures.  
Head and neck cancer stem cell sorting 
Informed consent was obtained from patients undergoing surgery for 
removal of HNSCC. All tumors were collected in accordance to the IRB 
protocols. The tumors obtained were cut and minced with a sterile scalpel until 
they could pass through a 25 ml pipette tip. They were suspended in a 9:1 
solution of DMEM-F12 (Hyclone, Waltham, MA) and Collagenase/Hyaluronidase 
(Stem Cell Technologies, Vancouver, BC, Canada). This mixture was then 
incubated at 370C for maximum of one hour and passed through a 10-ml pipette 
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every 15 minutes for mechanical dissociation. Cells were filtered through a 40-
μm nylon sieve (BD Falcon, NJ, USA), washed with low glucose complete DMEM 
and centrifuged at 800 rpm for 3 minutes. Single cell suspensions obtained from 
primary specimens (as well as from cell lines or xenografts) were washed, 
counted, and re-suspended at 1×106cells/ml PBS. The Aldefluor kit (Stem Cell 
Technologies) was used to identify cells with high ALDH activity. Briefly, cells 
were suspended with activated Aldefluor substrate (BAA) or the negative control 
(DEAB, a specific ALDH inhibitor) for 45 minutes at 370C. Then, cells were 
exposed to anti-CD44 (clone G44-26BD; Pharmingen, NJ, USA) and lineage 
markers (i.e. anti-CD2, CD3, CD10, CD16, CD18, CD31; BD Pharmingen). 
Mouse cells are identified using anti-H2Kd antibody (BD Biosciences, NJ, USA) 
and 7-Aminoactinomycin (7-AAD, BD Pharmingen) identified viable cells. Here 
and throughout this manuscript, studies were done in triplicate specimens per 
condition and three experiments were performed to verify reproducibility of the 
data.  
Stable Short Hairpin RNA Transduction  
Lentivirus expressing a short hairpin RNA (shRNA) construct for silencing 
IL-6 (Vector Core, University of Michigan) was generated in human 293T cells 
(human embryonic kidney cells) transfected using the Calcium Phosphate 
method, as described (Kaneko et al., 2006). Scrambled oligonucleotide 
sequence was used as control (shRNA-C). Supernatents were collected 48 hours 
after transfection and HDMEC cells were infected with it in a 1:1 dilution medium 
containing 4 µg/ml polybrene (Sigma-Aldrich, St. Louis, MO). Cells were selected 
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for 2 weeks and maintained in EGM2-MV supplemented with 1 µg/ml puromycin 
(InvivoGen, San Diego, CA). Down-regulation of IL-6 was confirmed by ELISA. 
Confocal Microscopy  
Paraffin tumor sections were deparaffinized in xylene and rehydrated in 
decreasing degrees of alcohols. Antigen retrieval was done using Dako Retrieval 
solution (Dako, CA) for 45 minutes at 980C. The anti-ALDH1 (BD Biosciences), 
anti-P-STAT3 (Santa Cruz 79993-R, CA), anti-IL6R and gp130 (abcam) were 
pre-labeled with Alexafluor 488 or 594 using the Zenon labeling kit (Invitrogen) 
and Confocal imaging was performed using Leica Inverted Confocal SP5X (Leica 
version 2.3.5; Los Angeles, CA). 
Immunohistochemistry 
Paraffin embedded sections were de-paraffinized in xylene and Antigen 
Retrieval was done using Dako antigen retrieval solution (Dako, CA). 
Immunostaining for ALDH1 (BD Biosciences, 61195, 1:100), IL-6 (abcam, 1:100), 
P-STAT3 (Santa Cruz, CA, 1:200), chromogenicity. Isotype matched 
immunoglobulins were used as negative controls.  
Orospheres 
Orospheres (i.e. spheroids of head and neck cancer-derived cells) were 
generated from FACS-sorted cells (5x103 cells/well) cultured in triplicate in low 
attachment plates (Corning Inc, NY,USA) (Krishnamurthy et al., 2010) and 
maintained in low glucose DMEM containing or not conditioned medium from 
HDMEC at a ratio of 3:1. Alternatively, cells were treated with HDMEC CM 
containing 0.4 µg/ml of anti-IL-6 (R&D Systems, Minneapolis, MN) or 10 µg/ml of 
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anti-IL-6R (Chugai Pharmaceuticals, Tokyo) or IgG isotype control or 20 ng/ml of 
rhIL-6. After 3 days, orospheres are visualized and quantified. 
SCID mouse model of human tumor angiogenesis  
Xenograft tumors vascularized with functional human microvessels were 
generated in severe combined immunodeficient (SCID) mice (CB17 SCID, 
Haslett, MI), as described (Nör et al., 2001). Briefly, 1,000 head and neck cancer 
stem cells (HNCSC- i.e., ALDH+CD44+Lin-) or 1,000 non-cancer stem cells 
(NCSC-ALDH-CD44-Lin-) were seeded with 5×105 cells of either HDMEC-
shRNA-C or HDMEC-shRNA-IL-6 in poly-(L-lactic) acid (PLLA; Medisorb) 
biodegradable scaffolds. Bilateral scaffolds were implanted subcutaneously in the 
dorsum of each mouse. Mice were monitored daily for tumor growth for the 
specified time periods in individual experiments. Alternatively, mice received 
scaffolds containing 5×105 HDMEC cells and 1×103 HNCSC or NCSCs. From 
Day 1, mice were treated with weekly intra-peritoneal injections of either 10 
mg/kg of humanized anti-IL-6R as described in Tsunenari et al., 1997, Shinriki et 
al., 2009 (Chugai Pharmaceuticals, Chuo-ku, Tokyo, Japan) or IgG. After 30 
days, mice were euthanized and tumors were retrieved, measured, weighed and 
processed. For the tumor evaluation of IL-6-/- immunodeficient mice, (a gift from 
Dr. Laurie McCauley, University of Michigan), WT and IL-6-/- mice were 
generated by standard homologous recombination techniques as described 
(Dalrymple et al., 1995, Dai et al., 2000). 
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Western Blots 
 40,000 ALDH+CD44+ or ALDH-CD44- cells from UM-SCC-74A, UM-
SCC-74B or primary head and neck cancer stem cells (HN-28) cells were plated 
in 6-well ultra-low attachment plates, serum starved overnight, and treated with 
endothelial cell conditioned medium (CM) or DMEM for the indicated time points. 
Alternatively, HNCSC and NCSC were exposed to HDMEC CM containing 0.4 
µg/ml of anti-IL-6 (R&D Systems, Minneapolis, MN) or 10 µg/ml of anti-IL-6R 
(Chugai Pharmaceuticals, Tokyo) or IgG isotype control. CM collected from 
HDMEC-shRNA-C or HDMEC-shRNA-IL-6 was used to treat the cells and 
western blots were performed. Primary antibodies were as follows: mouse anti-
human phospho-STAT3, rabbit anti-human STAT3, rabbit anti-human phospho-
ERK1/2, mouse anti-human ERK1/2 (Cell Signaling, Danvers, MA); rabbit anti-
human IL-6R (Santa Cruz), mouse anti-human gp130 (abcam, San Francisco, 
CA) and mouse anti-glyceraldehyde 3-phosphate dehydrogenase (Chemicon, 
Millipore, Billerca, MA). 
Enzyme-Linked Immunosorbent Assay  
Supernatents of triplicates of 24-hour endothelial or tumor cell cultures 
were collected and centrifuged to eliminate debris. IL-6 expression was 
determined using ELISA kits (Quantikine; R&D systems) according to the 
manufacturer’s instructions. Data was normalized by cell number. 
Invasion Assays  
HDMEC CM was pre-incubated with 0.4 µg/ml anti-IL-6 (R&D systems), or 
IgG control for 1 hour. 24-well companion plates (inserts) are pre-coated with 40 
101 
 
µl of 1:1 dilution of matrigel and serum free DMEM overnight. 400µl of HDMEC 
CM or CM from HDMEC-shRNA-C or HDMEC-shRNA-IL-6 was added to the 24-
well plates. ALDH+CD44+ and ALDH-CD44- cells (25×103 cells) were serum 
starved overnight, loaded onto the 8-µm pore sized cell culture inserts (Becton 
Dickinson, Franklin Lakes, NJ) having the matrigel layer. The cells are allowed to 
invade for 24 hours toward the stimulus like HDMEC CM. Unconditioned DMEM 
was used as control. Invaded cells were trysinized, collected and stained with 2 
µM Cell Tracker Green (Invitrogen) for one hour. Fluorescence was read at 
485/535 nm in a micro plate reader (Tecan, Salzburg, Austria). 
Laser Capture Microdissection 
A three step dissection procedure was done using a LCM microscope 
(Leica AS LMD; Leica Microsystems) with a pulsed 337 nm UV laser as 
described (Kaneko et al., 2007. Kaneko et al., 2009). Blood cells in the 
endothelial cells were excluded first. Then the endothelial cells lining the blood 
vessels were collected separately in a tube filled with TRIzol (Invitrogen) and 
immediately placed on ice. Then tumor cells adjacent to the blood vessels were 
collected in a different tube and quickly transported on ice to -800C. 
Reverse Transcription-Polymerase Chain Reaction (RT-PCR)  
Total RNA was extracted from the cells obtained by LCM or from the 
tumor cell line using TRIzol reagent (Invitrogen) and RNA was purified using 
RNAeasy Micro kit (Qiagen) as per the manufacturer’s instructions. The purity of 
the RNA was determined photometrically (Ultraspec 2000, Pharmacia Biotech, 
Germany). cDNA synthesis and PCR amplification were done in single tubes with 
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SuperScript one-step reverse transcription PCR (RT-PCR) and Platinum Taq kit 
(Invitrogen) using simultaneously a human IL-6 primer set and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) primer set. The sequence of the primers 
used here were as follows:  
IL-6, sense 5’-AAAGAGGCACTGGCAGAAAA-3’ and  
anti-sense 5’CAGGGGTGGTTATTGCATCT; and  
GAPDH, sense 5’-GACCCCTTCATTGACCTCAACT-3’, and  
antisense 5’-CACCACCTTCTTGATGTCATC-3’. 
 The PCR products were detected by standard agarose gels with 1.5% 
ethidium bromide. 
Statistical Analyses  
One-way ANOVA was performed using the SigmaStat 2.0 software 
(SPSS, Chicago, IL). Statistical significance was determined at *p<0.001 (unless 
otherwise specified). Statistics for the in vivo studies was performed by a 
Biostatistician with appropriate software as indicated.  
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Results 
A higher level of IL-6 mRNA is present in tumor associated endothelial cells 
than tumor cells. The identification of cell signaling pathways that promote 
cancer stem cell survival and self-renewal may lead to novel therapeutic targets 
for this specialized sub-population of cancer cells. The overall hypothesis 
underlying this study was to identify possible signaling molecules that might be 
integral to the interaction between head and neck cancer stem cells (HNCSC) 
and tumor associated endothelial cells.  
In a recent study, we identified that ALDH+CD44+Lin- cells had the 
properties of self-renewal, and tumorigenicity and were found spatially related to 
the tumor vasculature (Krishnamurthy et al., 2010). Selective ablation of the 
tumor associated endothelial cells using an inducible caspase system caused a 
decrease in the survival of ALDH+CD44+ cells in vivo. In recent years, there has 
been evidence of IL-6 promoting the self-renewal and survival of stem cells in 
breast and glial tissues (Sansone et al., 2007, Wang et al., 2009). However, the 
origin of the IL-6 in the IL-6-STAT3 pathway has been varied. In our study, we 
hypothesized that there might be a paracrine signaling of IL-6-STAT3 pathway 
initiated by the endothelial cells apart from a possible autocrine pathway which 
might be in existence. To test this, we performed laser capture microdissection 
as described (Kaneko et al., 2007, Kaneko et al., 2011) from 4 different primary 
HNSCC. The tumor cells and endothelial cells were collected separately and RT-
PCR analysis of these cells revealed a higher expression level of IL-6 mRNA in 
the tumor associated endothelial cells than the adjacent tumor cells (Figure 
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4.1A). We corroborated these findings in a head and neck cancer cell line, UM-
SCC-74A with primary endothelial cells (HDMEC) as well (Figure 4.1A). We also 
found statistically significant higher protein expression levels of IL-6 in primary 
endothelial cells compared to a panel of head and neck cancer cell lines, (UM-
SCC-74A, UM-SCC-74B, UM-SCC-17B) by ELISA (Figure 4.1B).  
Head and neck cancer stem cells express IL-6 receptors, IL-6R and gp130. 
To demonstrate the expression of IL-6R in cancer stem cells in primary 
HNSCC, we performed confocal imaging for co-localization of ALDH1 with IL-6R 
in 4 different patients and a representative image is shown (Figure 4.1C). Co-
localization of IL-6R (red) was seen only with ALDH1+ cells (green) 
demonstrating the relative expression of IL-6R in the ALDH1+ cells. The gp130+ 
cells were found both in ALDH1+ cells and ALDH1- cells in the primary HNSCC 
(Figure 4.1C). We also evaluated the expression of IL-6 receptors, IL-6R and 
gp130 in head and neck cancer cell lines, UM-SCC-74A and UM-SCC-74B 
(Figure 4.1D). Head and neck cancer stem cells, HNCSC; (i.e., 
ALDH+CD44+cells) expressed elevated levels of IL-6R than the parental cell line 
(unsorted cells) or the non-cancer stem cells (ALDH-CD44-). There was no 
significant difference in the gp130 levels between the cancer stem cells and non 
cancer stem cells.  
Endothelial cell-derived IL-6 promotes tumor initiation and growth in 
HNCSC. To evaluate specifically the role of endothelial cell initiated IL-6 events, 
we silenced the expression of IL-6 in primary endothelial cells (HDMEC) and 
confirmed the effectiveness of silencing IL-6 expression by ELISA (Figure 4.S.1). 
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To examine the role of endothelial cell derived IL-6 on tumor initiation of head 
and neck cancer stem cells in vivo, we isolated HNCSC (ALDH+CD44+Lin- cells) 
from 3 different patients of primary HNSCC (Patients 19, 20, 21) and implanted in 
immune-deficient mice with either 1,000 cells of HNCSC and 500,000 cells of 
HDMEC-shRNA-C or 1,000 cells of HNCSC and 500,000 of HDMEC-shRNA-IL-6 
(n=13) (Figure 4.2A). The tumor initiation graph demonstrated a significantly 
early initiation of tumors in the ALDH+CD44+Lin- +HDMEC-shRNA-C group than 
the ALDH+CD44+Lin- + HDMEC-shRNA-IL-6 group (Figure 4.2B). Tumor 
initiation was evaluated by both tumor palpability and the size of the scaffold to 
be greater than 75 mm3.  The tumor volumes of the individual mice demonstrate 
the earlier initiation and greater tumor volumes in the HDMEC-shRNA-C group 
compared to the xenografts generated from the HDMEC-shRNA-IL-6 group 
(Figure 4.2C). The assessment of the tumor volumes of the xenografts 
demonstrated that the tumor xenografts from the ALDH+CD44+Lin- + HDMEC-
shRNA-C group tumors initiated earlier and tumor volumes were greater than the 
HNCSC+HDMEC-shRNA-IL-6 group significantly until about 50 days of tumor 
implantation, after which the effect was decreased (Figure 4.2C). The average 
tumor volumes of the xenografts from the three different primary HNSCC in this 
study demonstrated a similar trend with the control group being significantly 
greater than the shRNA-IL-6 group at day 45 (Figure 4.2D). These studies 
suggested that endothelial cell secreted IL-6 actively promotes tumor initiation 
and tumor growth of head and neck cancer stem cells in vivo. 
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The frequency or density of cancer stem cells in a tissue has recently 
been suggested as a possible risk factor for poorer prognosis in patients 
(Neumeister et al., 2010). As a result, we wanted to study the effect of 
endothelial cell IL-6 on tumor initiation of different frequencies or numbers of 
cancer stem cells in the same genetic background (immunodeficient mice). We 
therefore implanted a serial dilution of 1000, 100 and 10 ALDH+CD44+Lin- cells 
from the same primary HNSCC (Patient 26) with either HDMEC-shRNA-C or 
HDMEC-shRNA-IL-6 cells. We also implanted scaffolds with no ALDH+CD44+ 
cells (0 cells) as negative controls. Tumor initiation or time to palpability of the 
individual groups (n=3) showed that greater the number of ALDH+CD44+cells, 
earlier is the initiation of tumors (Figure 4.3A). Nevertheless, tumors in the 
ALDH+CD44+cells + HDMEC-shRNA-C initiated tumors earlier than the 
HDMEC-shRNA-IL-6 group at the same density of cancer stem cells as seen in 
Figure 4.2 and no tumors were created in the 0 group as expected (Figure 4.3A). 
The overall trend for time to palpability was analyzed by eliminating the 0 group 
(as no tumors were initiated), and we found a significant delay in tumor initiation 
in the ALDH+CD44+Lin- + HDMEC-shRNA-IL-6 group (Figure 4.3B). The tumor 
volume over time demonstrates that ALDH+CD44+Lin- + HDMEC-shRNA-C 
group initiated tumors earlier and were greater in volume but the 
ALDH+CD44+Lin- + HDMEC-shRNA-IL-6 tumor xenografts gradually reached 
the control group by the end of the study (Figure 4.3C). The pair-wise statistical 
comparisons between different ALDH+CD44+ cell densities suggested greater 
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the initial numbers of cancer stem cells, greater the effect of IL-6 in promoting 
tumors (Figure 4.3D).  
IL-6 promotes survival of head and neck cancer stem cells in vivo. Our 
earlier studies demonstrated that endothelial cells in the vascular niche of the 
head and neck cancer stem cells promotes self-renewal and tumorigenicity of the 
ALDH+CD44+cells. Similar studies demonstrated that anti-angiogenic agents 
caused a decrease in the cancer stem cell survival in neural tissues (Calabrese 
et al., 2007). In our own work, we demonstrated that selective ablation of tumor 
endothelial cells caused a decrease in the cancer stem cell fraction 
(Krishnamurthy et al., 2010). To study if IL-6 might be a possible factor promoting 
survival of cancer stem cells in this interaction, we used our earlier strategy and 
implanted ALDH+CD44+Lin-cells from a primary HNSCC (Patient 22) with either 
HDMEC-shRNA-C or HDMEC-shRNA-IL-6 in immunodeficient mice for 30 days; 
n=3 (Figure 4.4A). The mice were euthanized by day 30 before host IL-6 could 
significantly contribute to the growth of the xenografts. The analysis of the cancer 
stem cell fraction revealed a significant decrease in the xenografts with the 
shRNA-IL-6 group (Figure 4.4B). Notably, there was an increase seen in the 
ALDH+CD44+ fraction of cells in the tumor xenografts arising from the control 
group suggesting there might be induction of self-renewal of the cancer stem 
cells in the presence of IL-6. We repeated this analysis with a head and neck 
cancer cell line, UM-SCC-74A, (n=6), wherein we observed that the control group 
initiated tumors earlier as expected (Figure 4.4C) and there was again a 
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significant decrease in the cancer stem cell fraction in the tumor xenografts of the 
HDMEC-shRNA-IL-6 group (Figure 4.4D).  
Our studies demonstrated that endothelial cell derived IL-6 promotes self-
renewal, survival and tumorigenicity of the cancer stem cells in vivo. However, 
the host-derived IL-6 was an important factor in this interaction. To address this 
key question, we generated tumor xenografts from ALDH+CD44+ and ALDH-
CD44- cells in WT type and IL-6-/- immunodeficient mice; a gift from Dr. 
McCauley, University of Michigan (Figure 4.4E). We observed that tumors from 
the ALDH+CD44+cells in the WT type mice were significantly greater in volume 
than the IL-6-/-mice at Day 120. On FACS analysis of the percent of the cancer 
stems, we observed a significantly decreased percent of ALDH+CD44+cells in 
the tumor xenografts from the IL-6-/- mice (Figure 4.4F). Taken together, our 
data suggests that IL-6 is an important molecule in the interaction of head and 
neck cancer stem cells with their micro-environment contributing to tumor 
initiation and growth. 
Head and neck cancer stem cells (ALDH+CD44+Lin- cells) co-relate with 
activated STAT3 pathway. The canonical IL-6 signal transduction pathway 
involves IL-6 ligand binding to the receptor IL-6R and to the common signal 
transducing receptor gp130. This activation propagates intracellular signaling of 
Janus kinases leading to the activation of STAT3. Activation of STAT3 has been 
related to self-renewal and stemness in various tissues including embryonic stem 
cells, intestinal stem cells and glioblastoma stem cells (Gao et al., 2007, Niwa et 
al., 1998, Matthews et al., 2011, Guryanova et al., 2011). To investigate the 
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possible relationship of activated STAT3 (p-STAT3) and head and neck cancer 
stem-like cells (ALDH+CD44+ cells) we analyzed by confocal imaging the spatial 
localization of ALDH1+ cells and phosphorylation of STAT3 in primary head and 
neck squamous cell carcinomas (HNSCC) (Figure 4.5A). DAPI was used to 
identify the nuclei and ALDH1+ cells were found to co-localize with p-STAT3 in 
primary HNSCC. Immunohistological examination of the tumor xenograft micro-
environment showed expression of ALDH1 and p-STAT3 around the tumor 
vasculature (Figure 4.5B, arrow indicates positive cells). We further compared 
the relative protein expression of p-STAT3, we isolated ALDH+CD44+Lin-cells 
and ALDH-CD44-Lin-cells from a primary HNSCC and evaluated the 
phosphorylation of STAT3 by Western Blot (Figure 4.5C). ALDH+CD44+ cells 
have an increased phosphorylation status compared to the ALDH-CD44- cells. 
Activation of the ERK pathway showed the reverse expression trend as expected 
since the ERK-MAPK pathway has been implicated in the differentiation of stem 
cells (Gu et al., 2011, Kim et al., 2011, Lin et al., 2010, Sakai et al., 2010). 
Similar phosphorylation pattern was seen in ALDH+CD44+ and ALDH-CD44- 
from the head and neck cancer cell line, UM-SCC-74A (Figure 4.5C).  To test 
whether endothelial cell secreted factors enhanced activation of STAT3; we 
exposed ALDH+CD44+ cells to serum-free endothelial cell CM (HDMEC) and 
analyzed the phosphorylation levels of STAT3 and ERK over time. We found that 
endothelial cell CM induced phosphorylation in ALDH+CD44+ cells suggesting 
that head and neck cancer stem cells have an activated STAT3 pathway which 
could be further induced by endothelial cell CM (Figure 4.5D).  
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Endothelial cell-derived IL-6 promotes self-renewal and invasion of HNCSC 
in vitro. To assess the functional role of endothelial cell secreted IL-6 on 
ALDH+CD44+ cells in vitro; we exposed the unsorted parental cancer cell line, 
UM-SCC-74A to endothelial cell CM either pre-treated with neutralizing antibody 
to IL-6 or IgG and measured the ALDH+CD44+ percent by flow cytometry (Figure 
4.6A). The quantification revealed that endothelial cell CM increased the cancer 
stem cell fraction which was reduced to parental levels in the presence of 
neutralizing antibody to IL-6 (Figure 4.6B). Treatment with rhIL-6 (20 ng/ml) also 
had an inductive effect on the percent of cancer stem cells, though to a lesser 
degree than endothelial cell CM (Figure 4.6B). This could possibly be due to 
additional factors in endothelial cell CM contributing to self-renewal or the 
possibility of CM containing more amounts of IL-6 than the rhIL-6 (20 ng/ml). The 
induction of phosphorylation of STAT3 by endothelial cell CM was decreased in 
the presence of neutralizing antibody to IL-6 (0.4 µg/ml) in the ALDH+CD44+ 
cells as seen by Western blot (Figure 4.6C). On generating orospheres from 
ALDH+CD44+ cells and ALDH-CD44- cells treated with endothelial cell CM with 
or without neutralizing antibody to IL-6 (Figure 4.6D), we observed greater 
number of orospheres arising from ALDH+CD44+ cells than from ALDH-CD44-
cells which was further induced on treatment with endothelial cell CM. 
Neutralizing IL-6 reversed this induction as seen in the graph (Figure 4.6E).  
The role of IL-6 on the self-renewal of ALDH+CD44+ cells was also tested 
using the Conditioned medium from the HDMEC-shRNA-IL-6 cells generated and 
used in the in vivo experiments. We also found an induction of the cancer stem 
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cell fraction of the parental cell line on treatment with the HDMEC-shRNA-C and 
HDMEC-shRNA-IL-6 CM (Figure 4.7A, 4.7B). The phosphorylation of STAT3 was 
also decreased on treatment with HDMEC-shRNA-IL-6 CM compared to 
HDMEC-shRNA-C CM (Figure 4.7C). We also analyzed the number of 
orospheres from the ALDH+CD44+ and ALDH-CD44- cells on treatment with the 
CM from the shRNA cells and observed similar trends of decreased self-renewal 
in the presence of shRNA-IL-6 CM group (Figure 4.7D). Taken together, these 
findings suggest that endothelial cell secreted IL-6 promotes self-renewal of head 
and neck cancer stem cells in vitro.  
Cancer stem cells being invasive and migratory are believed to cause 
secondary tumors (Biddle et al., 2011), and so we tested the invasive potential of 
ALDH+CD44+cells in the presence of HDMEC CM containing IL-6 and its 
absence in a transwell system coated with matrigel. The invasion assays 
revealed that the invasive potential of the ALDH+CD44+cells was inhibited in the 
presence of the neutralizing antibody to IL-6 or on treatment with HDMEC-
shRNA-IL-6 (Figure 4.S.2).  
Humanized IL-6R antibody decreases cancer stem cell survival and delays 
tumor initiation. Serum IL-6 levels have been shown to be an independent 
predictor of poor survival in head and neck squamous cell carcinoma patients 
(Duffy et al., 2008, Trikha et al., 2003, Hong et al., 2007, Chen et al., 1999). 
However, molecular targeting of IL-6 becomes challenging as individual patients 
have varying amounts of IL-6 and individualized therapy becomes necessary in 
the clinic. An alternative strategy to inhibit the IL-6-ligand initiated signaling would 
112 
 
be to target the IL-6R receptor and thereby prevent activation of STAT3. 
Tocilizumab is an FDA approved, humanized anti-human IL-6R antibody 
engineered by grafting the complementarily determining regions of a mouse anti-
human IL-6R into human IgG (Shinriki et al., 2009).  
The anti-IL-6R (10µg/ml) inhibited the induction of orospheres by the 
endothelial cell CM of HNCSC (Figure 4.8A) and decreased the phosphorylation 
of STAT3 in vitro (Figure 4.8B). To test the efficacy of inhibition of IL-6-IL-6R 
signaling on tumor initiation, we implanted ALDH+CD44+Lin- and ALDH-CD44-
Lin-cells from a primary HNSCC (Patient 34) with primary endothelial cells (n=6); 
and treated with IL-6R antibody (or IgG controls) from Day 1 post-implantation 
every week for four weeks intra-peritoneally at 10 mg/kg body weight (Figure 
4.8C). No significant weight reduction was observed in the mice during the 
course of this experiment (Figure 4.S.3). A hundred percent tumor initiation was 
observed in the IgG group (n=6), whereas only one tumor was created in the 
treatment group (IL-6R Ab) (Figure 4.8D). Tumor volumes at retrieval showed a 
greater volume in the IgG group compared to the treatment group (Figure 4.8E). 
Notably, there was a significant reduction in the cancer stem cell fraction 
(ALDH+CD44+Lin- cells) in the anti-IL-6R treated xenografts compared to the 
IgG control group (Figure 4.8F). 
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Discussion 
The poor survival and high recurrences in head and neck squamous cell 
carcinomas can be possibly explained by the cancer stem cell hypothesis. It was 
recently found in a prospective study of about 444 patients of HNSCC that high 
serum IL-6 levels was related with increased recurrences and poorer prognosis 
(Duffy et al., 2008). STAT3, a transcriptional factor activated by IL-6 has been 
found to be over-expressed in various tumors including HNSCC. Targeting 
cancer stem cells via the IL6/STAT3 pathway has been done in mammary 
tumors, lung adenocarcinomas and neural tumors (Sansone et al., 2007, Gao et 
al., 2007, Wang et al., 2009). The concept of IL-6 (an inflammatory stimulus), 
triggering a physiological mechanism of repair in the cancer tissue by stimulating 
proliferation and self-renewal of the cancer stem cells has been suggested 
(Sansone et al., 2007). 
In our earlier study, we demonstrated the sub-population of ALDH+CD44+ 
cells to be cancer stem-like in HNSCC (Krishnamurthy et al., 2010). We found 
that these cells exist in vascular niches and that tumor endothelial cell actively 
promoted self-renewal and survival of the cancer stem cells. In this study, we 
observed tumor endothelial cells synthesize greater amounts of IL-6 mRNA than 
the tumor cells (Figure 4.1). The protein expression of IL-6 is also greater in 
primary endothelial cells in comparison to a panel of head and neck squamous 
cell carcinoma cell lines. In fact, it was recently shown in Burkitt’s lymphoma, IL-6 
is secreted from thymic blood vessels in response to therapy and promotes the 
survival of Doxorubicin-resistant lymphoma cells (Gilbert and Hemann, 2010). 
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Work from lung carcinomas recently showed that endothelial cell secreted factors 
could regulate different aspects of cancer cell function such as invasion, 
proliferation and tumor growth in vivo (Franses et al., 2011).  
The activation of phosphorylation of STAT3 along with the presence of the 
IL-6R in the primary cancer stem cells demonstrated an active IL-6/IL-6R/STAT3 
pathway in the head and neck cancer stem cells. We observed active induction 
of self-renewal in the ALDH+CD44+cells via IL-6 from the endothelial cells in 
vitro which was significantly reduced in the presence of neutralizing antibody to 
IL-6. Though we observed an induction in the number of orospheres on treatment 
with rhIL-6, it was to a lesser degree than the induction by the endothelial cell 
conditioned medium. This suggests the possibility of other endothelial cell 
secreted factors that might contribute to the self-renewal of cancer stem cells. In 
fact, Interleukin-8 (CXCL-8) is a chemokine found in the cancer stem cells or its 
micro-environment and has been postulated as a therapeutic target for cancer 
stem cells in various tissues (Razmkhah et al., 2010, Ginestier et al., 2010, 
Hwang et al., 2011).  
In our study, we demonstrated that silencing the IL-6 gene in the 
endothelial cells alone resulted in a delay in the tumor initiation and growth of 
tumor xenografts arising from the ALDH+CD44+ cells (Figure 4.2). However, this 
effect was depreciated after 50 days which could possibly be explained by the 
host IL-6 contributing to the tumor environment. It is also a distinct possibility that 
the endothelial cells stably expressing shRNA-IL-6 clone had been lost and 
replaced by normal cells. Nonetheless, our studies demonstrated an important 
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role of IL-6 cells and its micro-environment composed of tumor endothelial cells. 
In our work, although we demonstrated the increased expression of IL-6 in the 
endothelial cells relative to the tumor cells (Figure 4.1); this does not preclude the 
possibility of an existing autocrine IL-6 pathway in the head and neck cancer 
stem cells. Moreover, we did not examine the relative IL-6 levels in the cancer 
stem cells compared to the non-cancer stem cells. In glioblastoma stem cells, the 
non cancer stem cells were found to have increased IL-6 expression levels than 
the cancer stem cells and were found to be the source of IL-6 signaling (Wang et 
al., 2009).  
The importance of IL-6 on tumor initiation, irrespective of its source was 
demonstrated in our work on the xenografts generated from the IL-6-/- immuno-
deficient mice (Figure 4.4). We observed the tumor growth over time for four 
months and still found a significant difference in tumor volumes between the WT 
type and the IL-6-/- mice unlike using the shRNA strategies wherein the effect is 
lost by 80 days. This demonstrates that IL-6 derived from different sources can 
potentially promote tumor initiation of cancer stem cells. Thereby, targeting IL-6 
signaling pathway could be beneficial to patients with squamous cell carcinomas. 
In fact, CNTO328, an anti-IL-6 chimeric monoclonal antibody is in clinical trials 
for refractory multiple myelomas and B-cell Non-Hodgkin’s lymphoma (van 
Zaanen et al., 1996, Voorhees et al., 2009). The fact that serum IL-6 levels has 
been related to increased tumor recurrences and poorer prognosis (Duffy et al., 
2008) and in our work we see an increased tumor initiation in the presence of IL-
116 
 
6, suggests that Interleukin-6 could also be a potential prognostic marker in 
patients with head and neck squamouc cell carcinomas.  
Tocilizumab (Actemra) is a humanized monoclonal antibody against IL-6R, 
recently approved by the FDA for use in autoimmune disorders. The use of anti-
IL-6R in our model delayed the tumor initiation by preventing the activation of 
STAT3 (Figure 4.8). Moreover, the analysis of the cancer stem cells in our 
xenografts showed a significant decrease in the Tocilizumab treatment group 
suggesting that inhibition of IL-6 signaling decreases the survival of the head and 
neck cancer stem cells. The in vitro invasion data (Figure 4.S.2) suggested that 
the invasive potential of the head and neck cancer stem cells is increased in the 
presence of IL-6 which could translate into metastasis in vivo. In fact, in a recent 
study, targeting STAT3 with Cucurbitacin I inhibited tumorigenicity and distant 
metastasis of head and neck cancer stem cells (Chen et al., 2010).  This might 
suggest a role of IL-6/STAT3 signaling in EMT transition of cells as seen in 
breast cancers (Sullivan et al., 2009). Although the complete mechanism of 
ALDH+CD44+ cells is still unclear, our data suggests that IL-6/STAT3 paracrine 
signaling with the micro-environment might possibly be involved with the tumor 
initiation and even progression of cancer stem cells  
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Figure 4.1. Analysis of IL-6 expression in tumor endothelial cells and IL-6R 
in head and neck cancer stem cells. (A) RT-PCR showing the mRNA 
expression of IL-6 in tumor cells compared to the tumor endothelial cells obtained 
by Laser Capture micro-dissection from primary HNSCC. Similar trend is 
observed in the expression of IL-6 in a head and neck cancer cell line, UM-SCC-
74A to primary endothelial cells (HDMEC). (B) Graph showing Interleukin-6 
levels in primary endothelial cells (HDMEC) compared to three different head and 
neck squamous cell carcinoma cell lines, UM-SCC-74A, UM-SCC-74B, UM-
SCC-17B obtained by ELISA. Data was normalized by cell number (*p<0.001). 
(C) Confocal microscopy of primary human HNSCC (patient 15) immunostained 
for ALDH1 (green) and IL-6R (red) or gp130 (red) and DAPI to identify nuclei. 
The overlay image shows the co-localization of the ALDH-positive cells with the 
IL-6R-positive cells. (D) Western Blot for IL-6R and gp130 in head and neck 
cancer stem-like cells (ALDH+CD44+cells) and non-cancer stem cells (ALDH-
CD44-cells) in HNSCC cell lines, UMSCC-74A and UM-SCC-74B. 
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Figure 4.2. Endothelial cell secreted IL-6 promotes tumor initiation and 
growth of head and neck cancer stem-like cells. (A) Schematic representation 
of the approach used for testing the role of endothelial cell secreted IL-6 on the 
tumorigenic potential of ALDH+CD44+ cells in primary tumors. ALDH+CD44+Lin-
cells were isolated from 3 different primary HNSCC and implanted in immuno-
deficient mice along with HDMEC-shRNA-C or HDMEC-shRNA-IL-6. (B) Graph 
shows the relative occurrence of time to palpability of tumors (i.e., the time at 
which tumors are initiated) in the ALDH+CD44+Lin- tumors with HDMEC-shRNA-
C or with HDMEC-shRNA-IL-6. (C) Graph shows the tumor volume of the 
individual mice (n=13) obtained by the implantation of ALDH+CD44+cells with 
HDMEC-shRNA-C or HDMEC-shRNA-IL-6. (D) Graph shows the relative tumor 
volumes of the two groups obtained from the three different patients at Day 45.  
*p<0.05. 
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Figure 4.3. Endothelial cell secreted IL-6 promotes tumor initiation of 
ALDH+CD44+cells relative to their cell numbers. (A) ALDH+CD44+Lin- cells 
were isolated from a primary HNSCC (Patient 26) and implanted in serial 
dilutions of 1000, 100, 10 or 0 cells along with 500,000 cells of HDMEC-shRNA-
C or HDMEC-shRNA-IL-6 in immunodeficient mice. Graph shows the relative 
occurrence of tumor initiation in the various individual groups. (B)  Tumors  
generated from ALDH+CD44+cells with HDMEC-shRNA-C or with HDMEC-
shRNA-IL-6 group irrespective of the ALDH+CD44+cell numbers was expressed 
as an overall tumor initiation graph after eliminating tumors that did not occur (0 
group). (C) Graph shows the tumor volume of the individual groups obtained by 
the implantation of ALDH+CD44+cells with HDMEC-shRNA-C or HDMEC-
shRNA-IL-6. (D) The pairwise statistics for the different frequencies of 
ALDH+CD44+cells (10,100, 1000) that created tumors was determined using the 
Bonferroni correction and established to be *p<0.0125. 
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Figure 4.4. Endothelial cell secreted IL-6 promotes survival and self-
renewal of head and neck cancer stem cells in vivo. (A), ALDH+CD44+Lin- 
cells isolated from a primary HNSCC (Patient 22) and implanted with HDMEC-
shRNA-C or HDMEC-shRNA-IL-6. (B) Tumors retrieved after 30 days and 
percentage of ALDH+CD44+ fraction is evaluated in primary tumors and 
xenografts. (C) Graph represents the tumor initiation of ALDH+CD44+cells from 
UM-SCC-74A, implanted with HDMEC-shRNA-C or HDMEC-shRNA-IL-6 (n=6) 
(D) percent of ALDH+CD44+cells in the xenografts compared to the parental cell 
line (E) Tumor volumes from ALDH+CD44+Lin- cells and ALDH-CD44-Lin- cells 
in WT type and IL-6-/- immunodeficient mice from a primary HNSCC (Patient 36). 
(F) Cancer stem fraction (ALDH+CD44+Lin-cells) in the tumor xenografts 
compared to the primary tumor. 
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Figure 4.5. Endothelial cell-derived factors activate STAT3 pathway in head 
and neck cancer stem-like cells (A) Single cell co-localization of head and 
neck cancer stem-like cells (ALDH1+) cell with phospho-STAT3 as visualized by 
confocal imaging in a primary HNSCC. DAPI identifies the nuclei and the merged 
image shows the co-localization of ALDH1 and P-STAT3. (B) Immunohistological 
representation of ALDH1+cells and p-STAT3+ in a peri-vascular localization 
(arrows) in tumor xenografts generated from primary ALDH+CD44+cells. (C) 
Baseline phosphorylation of STAT3 in head and neck cancer stem-like cells 
(ALDH+CD44+) compared to non-cancer stem-like cells (ALDH-CD44-) in a 
primary HNSCC (Patient 28); and a head and neck cancer cell line, UM-SCC-
74A. (D) Western blot for phosphorylated and total STAT3, ERK in 
ALDH+CD44+ cells on treatment with endothelial cell conditioned medium. 
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Figure 4.6. Endothelial cell secreted IL-6 signaling promotes self-renewal of 
head and neck cancer stem-like cells in vitro. (A) FACS analysis of UM-SCC-
74A cells treated with endothelial cell CM with or without neutralizing antibody to 
IL-6 for 48 hours. The quantification of triplicates of treatment is depicted in (B). 
(C) ALDH+CD44+ and ALDH-CD44- cells, serum starved and exposed to 
endothelial cell CM with and without neutralizing antibody to IL-6. 
Phosphorylation of STAT3 was detected by Western Blot. (D) photomicrographs 
of representative orospheres arising from ALDH+CD44+ and ALDH-CD44-cells 
and cultured under low attachment plates. Cells were treated with endothelial cell 
CM with and without neutralizing antibody to IL-6 and quantified in (E).  
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Figure 4.7. Effect of HDMEC-shRNA-IL-6 on self-renewal of head and neck 
cancer stem-like cells. (A) UM-SCC-74A treated with HDMEC-shRNA-C or 
HDMEC-shRNA-IL-6 CM for 48 hours and the cancer stem cell fraction is 
determined by FACS. The quantification is seen in (B). (C) ALDH+CD44+ and 
ALDH-CD44- cells were serum starved and exposed to HDMEC-shRNA-C or 
HDMEC-shRNA-IL-6 CM for 30 minutes. Phosphorylation of STAT3 was 
detected by Western Blot. (D) Orospheres arising from ALDH+CD44+ and 
ALDH-CD44- cells cultured under low attachment plates and treated with 
HDMEC-shRNA-C, HDMEC-shRNA-IL-6 or unconditioned DMEM and is 
quantified.   
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Figure 4.8. Tocilizumab or humanized anti-IL-6R antibody inhibits self-
renewal and tumor initiation of head and neck cancer stem cells in vitro 
and in vivo. (A) Graph represents the relative number of orospheres arising from 
ALDH+CD44+ and ALDH-CD44- cells in the presence and absence of anti-IL-6R 
(10µg/ml) with HDMEC CM. (B) represents the phosphorylation of STAT3 on 
treatment with anti-IL-6R (10µg/ml). (C) Scheme of the preventive regimen for 
tumor initiation of ALDH+CD44+Lin-cells and ALDH-CD44-Lin-cells from a 
primary HNSCC (Patient 34). Mice are treated every week IP with IgG or anti-IL-
6R for 4 weeks from Day 1. (D) Graph shows the time for tumor initiation in the 
IgG group and the anti-IL-6R treatment group in one month. (E) Represents the 
relative tumor volumes at retrieval in the individual groups and the cancer stem 
cell fraction (i.e., ALDH+CD44+Lin-cells) in (F). 
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Figure 4.S.1 ELISA for IL-6 expression in HDMEC transfected with shRNA-C 
or shRNA-IL-6. (A) HDMEC were transfected with shRNA-C or shRNA-IL-6 for 
48 hours and cells were selected for two weeks. Data is normalized by cell 
number.  
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Figure 4.S.2 Head and neck cancer stem cell invasion. (A) Head and neck 
cancer stem cell (ALDH+CD44+) invasion was evaluated in the presence of 
endothelial cell CM with or without neutralizing antibody to IL-6. (B) 
ALDH+CD44+ cell invasion was evaluated in the presence of HDMEC-shRNA-C, 
HDMEC-shRNA-IL-6 or unconditioned DMEM.  
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Figure 4.S.3 Comparable mice weights on treatment with anti-IL-6R. Graph 
shows the relative weights of the mice in the IgG group and the anti-IL-6R 
treatment group during the course of the study (30 days). 
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CHAPTER V 
 
CONCLUSION 
 
 
Head and neck squamous cell carcinomas contain a sub-population of 
highly tumorigenic cells that exhibit self-renewal and multipotency. These cells 
can be isolated from primary head and neck squamous cell carcinomas using 
Aldehyde Dehydrogenase (ALDH) activity and CD44 expression, and have been 
named head and neck cancer stem cells (HNCSC). It has been proposed that the 
HNCSC are the “drivers” of head and neck tumor progression, and therefore 
have to be eliminated to achieve cancer cure. However, little is known about 
mechanisms underlying the survival and self-renewal of HNCSC. The hypothesis 
underlying this dissertation is that head and neck cancer stem cells (i.e. 
ALDH+CD44+) are localized in the perivascular niche and depend on endothelial 
cell-secreted factors for their survival and self-renewal. 
Here, we observed that HNCSC are found in close proximity to blood 
vessels in primary head and neck squamous cell carcinomas. Endothelial cell-
secreted factors promoted the proliferation, self-renewal and survival of HNCSC 
in vitro, as evidenced by the increase number of orospheres (i.e. non-adherent 
colonies of cells) formed in soft agar or ultra-low attachment plates. In vivo, 
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selective ablation of tumor endothelial cells caused a marked decrease in the 
fraction of HNCSC suggesting that cancer stem cells depend on intact 
perivascular niches for their survival. 
In our search for a possible mechanism to explain the dependency of 
HNCSC on endothelial cells, we observed that cancer stem cells have a 
constitutively active IL-6R/STAT3 pathway, while tumor endothelial cells secrete 
high levels of IL-6. Inhibition of endothelial cell IL-6 caused a decrease in the 
self-renewal and tumorigenicity of the HNCSC. Notably, a humanized antibody to 
IL-6R delayed tumor initiation and decreased the survival of HNCSC in vivo. 
Collectively, these results unveil the endothelial cell-secreted factors as critical 
regulators of HNCSC survival and self-renewal, and suggest that patients with 
head and neck cancer might benefit from targeted therapies against cancer stem 
cells.  
Our understanding of the pathobiology of head and neck squamous cell 
carcinomas has been steadily increasing in the last couple of decades. Despite 
these various advances in prevention and treatment of HNSCC, the 5-year 
survival rate has not significantly increased. This poor prognosis is primarily due 
to the increased recurrences seen in head and neck cancers. The cancer stem 
cells, the sub-population of cells which are believed to be tumorigenic, are 
hypothesized to be responsible for the recurrences seen in cancers. With this 
perspective in mind, we wanted to explore the characteristics of the cancer stem 
cells in HNSCC and try to identify the micro-environment in which they exist. 
Little is known about the molecular mechanisms that distinguish the head and 
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neck cancer stem cells from the rest of the tumor cells. The identification of novel 
molecular mechanisms that regulate these cells would be critical in developing 
targeted therapy against head and neck cancer stem cells. 
In Chapter III, we demonstrated that ALDH+CD44+Lin- cells from primary 
HNSCC had a cancer stem-like phenotype. We demonstrated that only a 1000 
cells of the ALDH+CD44+ cells could generate tumors consistently compared to 
the 10,000 cells of the ALDH-CD44- cells. Moreover, the tumor xenografts we 
generated from the ALDH+CD44+ cells resembled the primary tumors 
histologically. We demonstrated their self-renewal and developed an assay to 
study and expand cancer stem cells in vitro which we termed the “orosphere 
assay” in Chapter II. These ALDH+CD44+ cells could also be differentiated to 
their parental cell line on culturing under regular attachment conditions thus 
satisfying the two tenets of making the ALDH+CD44+ cells as cancer stem cells 
in head and neck squamous cell carcinomas.  
Cancer stem cells are being targeted in various cancers today either in 
lieu of their altered genetic signature or due to their dependence on their micro-
environment or their niche. The cancer stem niche in HNSCC had not been 
identified. In Chapter III, we set out to identify a possible peri-vascular niche for 
the ALDH+CD44+ cells. In our study of the normal mucosa, we identified the 
stem cells (ALDH1+) cells to be found in the basal layer of the stratified 
epithelium as seen in the stem cells of the skin. However, in primary cancers we 
observed a spatial relationship of the ALDH1+cells to the vasculature. We 
observed that every ALDH1+ cell in 8 different patients with HNSCC was found 
140 
 
within a distance of 100 µm of a blood vessel. We were intrigued by this 
localization and decided to study the possible role of endothelial cells on the 
cancer stem cells. 
          One of the first things we decided to explore in the possible crosstalk 
between the endothelial cells and head and neck cancer stem cells was to study 
non-contact cell-cell interaction. As a result, we collected Conditioned media from 
endothelial cells and studied the effects of endothelial cell secreted factors on the 
cancer stem cells. We found that the factors from endothelial cell Conditioned 
medium had an induction in the expression of Bmi-1 and increased number of 
orospheres; demonstrative of self-renewal in the head and neck cancer stem 
cells. At this time, it was necessary to perform in vivo assays showing the 
importance of the endothelial cells in the tumorigenicity and the survival of the 
cancer stem cells. We addressed this by two independent strategies, we 
generated tumor xenografts from ALDH+CD44+ cells either in the presence or 
absence of the endothelial cells and we showed that the tumor growth is greater 
in the presence of endothelial cells. Alternatively, we generated tumor xenografts 
with endothelial cells transduced with an inducible caspase-9 which we could 
selectively induce apoptosis, and then examined the survival of the cancer stem 
cell fraction and saw that the loss of tumor endothelial cells decreased the 
survival of the cancer stem cell fraction. 
          In Chapter IV, we tried to dissect the endothelial-stem cell crosstalk and 
identify the possible factors in the endothelial cell CM which promoted the self-
renewal and survival of the head and neck cancer stem cells. In primary HNSCC, 
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we demonstrated the increased IL-6 mRNA expression in the tumor endothelial 
cells than tumor cells. We also observed that ALDH+CD44+ cells have an 
activated STAT3 pathway, a downstream target of IL-6. Using an antibody 
against IL-6 and shRNA-IL-6 approaches, we demonstrated that endothelial cell 
secreted IL-6 induced self-renewal of the ALDH+CD44+ cells. There was an 
increased tumorigenicity in the presence of IL-6 which was significantly lost or 
delayed in the absence of IL-6 as demonstrated by our transgenic mice (IL-6-/- 
mice and our shRNA-IL-6). We also observed a significant reduction of the 
cancer stem fraction (ALDH+CD44+) in the tumor xenografts suggesting the 
importance of IL-6 in maintenance of the cancer stem cells in vivo.  
          At this point, we were interested in developing an agent to interfere in the 
endothelial cell–cancer stem cell interaction to potentially translate as an 
adjuvant therapy to delay recurrences. With this long-term perspective, we used 
Tocilizumab, an FDA approved humanized anti-IL-6R antibody (Chugai 
Pharmaceuticals), in an in vivo study and showed that interfering with the IL-6 
signaling causes a delay in the tumor initiation and a concomitant decrease in the 
cancer stem cell fraction. In Figure 5.1, we propose a model that has been 
described in this dissertation. The cancer stem cells (ALDH+CD44+) in head and 
neck squamous cell carcinomas are found in a vascular niche. The endothelial 
cells secrete various factors which promote the self-renewal and survival and 
tumorigenicity of the cancer stem cells (Chapter III). One such molecule is the 
inflammatory cytokine IL-6. IL-6 secreted from the tumor endothelial cells bind to 
the cancer stem cells via IL-6R and activates STAT3. Self-renewal is induced as 
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a result of this, cancer stem cells increase in number, and tumor growth ensues. 
Interference of the IL-6/IL-6R signaling by either antibody against IL-6 or use of 
the anti-IL-6R antibody, caused a decrease in the survival of the cancer stem 
cells; loss of the tumor initiating cells and delay in tumor growth and recurrences. 
The specific conclusions of this dissertation are: 
1. ALDH+CD44+ cells are cancer stem-like cells in head and neck cancers. 
2. ALDH+CD44+cells exist in vascular niches and the endothelial cells 
secrete factors that promote their self-renewal and tumorigenicity. 
3. The orosphere assay might prove to be a valuable tool to study and 
expand cancer stem cells in vitro. 
4. Endothelial cell initiated IL-6/IL-6R/STAT3 pathway promotes self-renewal, 
survival and tumor initiation of the head and neck cancer stem cells in 
vivo.  
          In summary, our work demonstrates that endothelial cells play an integral 
role in the maintenance and survival of head and neck cancer stem cells. 
Targeting cancer stem cells either via their niche or by exploring the specific 
molecular mechanisms that regulate them would result in newer, better 
therapeutics benefiting patients with HNSCC. Though beyond the scope of this 
project, the concept of re-programming (differentiated cells re-acquiring the 
characteristics of stem cells) would also be an area that merits detailed study. In 
fact, the fact that ALDH-CD44-cells could induce limited tumorigenicity and scope 
of forming tumors would lend credence to this theory.  
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Figure 5.1. Illustrative representation of IL-6-IL-6R signaling in head and 
neck cancer stem cells. HNSCC is a heterogenous tissue with a few cancer 
stem cells (ALDH+CD44+). Tumor associated blood vessels provide a vascular 
niche and secrete factors including IL-6 which binds to IL-6R on the cancer stem 
cells. IL-6-IL-6R activates STAT3 pathway and results in self-renewal of 
ALDH+CD44+ cells and tumor growth. Inhibition of activation of IL-6 pathway 
either by antibodies to IL-6 or to IL-6R prevents the activation of the pathway, 
decreased survival and proliferation of the cancer stem cells and tumor initiation 
and volume decreased. 
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APPENDIX 
 
LIST OF PROTOCOLS 
 
 
1. Tumor Dissociation Protocol: for primary tumors and xenografts 
2. Head and neck cancer stem cell isolation via Fluorescence Activated Cell 
Sorting (FACS) for ALDH and CD44 
3. Suspension Cultures: 
A, Orospheres 
B, Colony Formation Assay 
4. Immunohistochemistry for ALDH1 
5. Cell localizations using Confocal Imaging for ALDH1, CD44, P-STAT3, IL-
6R, gp130 
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Tumor Dissociation Protocol 
Purpose: To obtain single cell suspensions of primary head and neck squamous 
cell carcinomas or tumor xenografts 
Materials Required: 
1. Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen) with 10% Fetal 
Bovine Serum (FBS Gibco 10082; Invitrogen), 1% Antibiotic  Antimycotic 
Solution (AAA, Sigma A5955; St. Louis, MO) 
2. DMEM/F12 (no supplements, Hyclone, Waltham, MA) 
3. Collagenase /Hyaluronidase (Stem Cell Technologies 07912; Vancouver, 
BC, Canada) 
4. ACK Lysing Buffer (Gibco A10492) 
5. 40 μm nylon mesh or sieve (BD Falcon 352340; Franklin Lakes, NJ) 
General Instructions: 
Please use a disposable gown, mask, gloves while working with primary 
samples. 
Procedure: 
1. Obtain tumor specimens (primary samples from OR or xenografts from 
mice) and place it immediately in complete DMEM or transport media. 
             Note: This complete DMEM has 10% FBS and 1% AAA  
2. Pour off most of the media leaving about 5 ml with the sample. Wash the 
sample with the DMEM complete media, 3-4 times (essential with the 
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primary samples so that we can surface clean the samples for bacterial 
and fungal pathogens).  
      Note:  i) This is vital especially if we culture primary samples subsequently 
as it helps minimize contamination. 
                ii) Please do not vacuum out the media during washing, decant the 
old media and add fresh media to wash gently, this helps in preventing 
possible contamination and also minimizes cell lysis. 
3. Place tumor and 5 ml of the same complete media in a sterile petri dish.  
Note: 1. Do not use tissue culture dishes. 
Mince the tumor with sterile scalpel/razor blade until no large chunks are 
seen. The tumor pieces should pass through a 25ml pipette. 
Note: This is a critical step; chop the tumor in one direction to small pieces 
and then re-cross them in the opposite direction as minimally as possible. 
Use of too much force lyses the cells resulting in low number of viable cells. 
4. Place the minced tumor in a 50ml conical tube and fill up to 25-30 ml with 
plain DMEM/F12.  
Spin at 800 rpm, 4
.
C for 3 minutes to wash. 
5. Carefully decant media and place tumor pellet in the petri dish. 
6. Dilute 1 ml of 10X collagenase/Hyaluronidase in 9 ml DMEM/F12. Take 5 
ml of the solution. Wash the 50 ml tube with enzyme solution and pipette 
gently on the sample. Repeat with the final 5 ml of enzyme solution.  
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Note: this is done so that there are no tumor chunks/cells left in the tube. 
You can go down to about 6-7 ml of this solution to conserve the enzyme 
especially with tumor xenografts. 
7. Mix the tumor/enzyme solution well so that you have a homogenous 
mixture and place in the incubator at 37
.
C for 15 minutes. Remove from 
the incubator and pipette the entire mixture through a 25 ml pipette to 
mechanically dissociate tumor chunks. Repeat this every 15-20 minutes 
for a maximum of about 1 hour. As you observe tumor dissociation move 
from a 25 ml pipette down to a 10 ml pipette to ensure proper dissociation. 
       Note: i) Do not leave the tumor sample in collagenase more than an hour 
and 15 minutes as this becomes too traumatic to the cells and ensures poor 
cell viability. 
                ii) While mechanically dissociating using pipettes use a little 
pressure to suck in the tumor pieces and splash it down against the wall of 
the Petri dish for maximal dissociation. 
8. Place a 40 m sieve in a fresh 50 ml conical tube. Collect the tumor/single 
cell suspension and pipette into the sieve. If flow stops, place the pipette 
on the bottom of the sieve and “suck up” to create a vacuum to ensure 
flow through the sieve.  
[Note: To start or establish cell lines in vitro, place chunks of tumor pieces 
in a T-25 with appropriate medium with AAA. Change media daily to 
prevent contamination and observe]. 
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9. The filtrate has the single cell suspension. Neutralize the collagenase with 
FBS at approx. the ratio of 80-20% (to the filtrate solution say 8 ml add 2 
ml of FBS). Spin for 3 minutes at 800 rpm at 4
.
C. 
10. Observe the cell pellet after centrifugation. Decant neutralized enzyme 
mixture to obtain cell pellet.  
               Note: The cell pellet may not be visible especially in biopsy samples. 
So, decant the supernatant carefully to avoid losing the cancer cell suspension. 
11. Re-suspend the cell pellet in 5 ml of ACK lysing buffer for 1 minute for 
RBC cell lysis. Spin down at 800 rpm for 3 minutes.  
Note:  You will see a change in color of the cell pellet from pinkish to a 
clearer white. Continue with any protocol you are working with. 
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Head and neck cancer stem cell isolation via Fluorescence Activated 
Cell Sorting (FACS) for ALDH and CD44 
 
Materials Required: 
1. Aldefluor substrate and its inhibitor, DEAB (Aldefluor kit, Stem Cell 
Technologies, 01700; Vancouver, BC, Canada). 
2. CD44 antibody, conjugated with APC (BD Pharmingen, 559942; Franklin 
Lakes, NJ) 
3. IgG antibody conjugated with APC (BD Pharmingen, 550931) 
4. 7AAD (eBioscience, 00-6993-50; San Diego, CA) 
Procedure: 
1. Obtain single cell suspension from cell lines either by trypsinizing or 
digesting tumor specimens from patient/xenografts. 
2. Count the cells and distribute cells in Flow cytometry tubes (11 75 tubes) 
at 1 106 cells per tube in 1 ml of Aldefluor Buffer.  
Note:  i) You can go up to a maximum of 4-5 million cells for the same 
staining efficiency. I personally recommend using about 3- 3.5 million cells 
per tube. 
           ii) Cell count is very important for reproducible, consistent response 
of aldefluor  activity.  
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          iii) Aldefluor is very sensitive to light exposure, volume of buffer and 
temperature. 
        3. Label the flow cytometry tubes per condition along with controls as 
follows:  
                A. a Blank tube (only cells in PBS for negative control) 
                B. a 7AAD tube (for cell viability) 
                C. an IgG-APC tube (IgG control for CD44) 
                D. a DEAB tube (a negative inhibitor for Aldefluor substrate) Keep this 
tube empty no cells added. 
                E. Test tubes are labeled from T1, T2 and so on according to the 
number of cell availability and requirement.  
      4. In the tubes, add cells (3- 3.5 million cells) in Aldefluor buffer to all the 
tubes except the DEAB. Turn off the lights in the hood. 
5. Step-wise activation of Aldefluor: 
6. Add 5 l of DEAB solution to the DEAB tube and 5 l of the activated 
aldefluor substrate to T1. Transfer 0.5 ml of this activated solution with 
cells to the DEAB tube.  
Note: i) This is done in this order for the DEAB to be functional. Quick 
addition of the activated solution to the DEAB tube is important for 
inhibition. 
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         ii) All fluorochromes being light sensitive please work under dark 
conditions (no lights on in the hood).  
7. Add 5 l of activated Aldefluor substrate to the rest of the test tubes. 
Incubate the DEAB and the test tubes for about 45 minutes at 37
.
C 
covered in Aluminium foil (minimum time 30 minutes, do not exceed 1 
hour, best result is at 35-45 minutes) 
               Note:   Aldefluor is light sensitive, work in the dark, keep wrapped in 
aluminum foil. 
After the incubation, spin down the cells at 800 rpm for 5 minutes and re-
suspend the cell pellets in 1 ml of Aldefluor Buffer. 
Note: This step is important to terminate the activation of the aldefluor. 
8.  Add 5 l of CD44-APC antibody (1:50) to the test tubes and the DEAB 
tube and IgG to the control tube. Store on ice. 
9. Add the 7AAD to the test tubes and DEAB tube in the same ratio along 
with the 7AAD control tube. 
10. Keep all the tubes in ice, covered in Aluminium foil  
11. Collection tubes are labeled as (ALDH+CD44+) and ALDH-CD44- with 1 
ml of complete media (DMEM Low glucose, 10% FBS, 1% Penicillin 
Streptomycin). 
12. The cells are ready to be sorted now using FACS. The Aldefluor activity 
can be detected for a maximum of 24 hours. Store and transport samples 
for sorting in ice covered with Aluminium foil for best results. 
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General Instructions: 
1. For sorting of primary tumors, please use the Lineage specific cocktail to 
eliminate lineages.  
CD2  (BD Pharmingen, 555328; Franklin Lakes, NJ) – to detect T-cells 
and N-Killer cells 
CD3  (BD Pharmingen, 555334; Franklin Lakes, NJ)-   to detect T-
lymphocytes 
CD10 (BD Pharmingen, 555376; Franklin Lakes, NJ)-  to detect B-cells  
CD16 (BD Pharmingen, 555408; Franklin Lakes, NJ)-  to detect 
neutrophils, monocytes, macrophages 
CD18 (BD Pharmingen, 557528; Franklin Lakes, NJ)- to detect integrins 
associated with macrophages and lymphocytes 
Note: all these antibodies are pre-conjugated with PE-cy5 (1:50). They 
detect cells of the hematopoietic origin like T-cells, Natural Killer cells, 
monocyte-macrophages, B-cells, neutrophils which is eliminated.  Use 
about 3 µl/sample. 
2. During sorting of mouse xenografts, to eliminate mouse cells, please add 
to test tubes and to a separate color control tube for PE,  
anti H2kD Biotinylated (1:100); (BD Pharmingen, 553564; Franklin Lakes, 
NJ) and 
PE streptavidin (BD Pharmingen, 554061; Franklin Lakes, NJ).  
Use about 4 µl of each and wait for 10-15 minutes on ice between them. 
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3. To eliminate human endothelial cells from the xenografts use 5 µl of  
PE- CD31 (BD Pharmingen, 560983; Franklin Lakes, NJ) in test tubes and 
add a control tube as well. 
 
Contact Personnel: 
1. Ann Marie Deslauriers                             adeslaur@umich.edu 
2. Michael Pihalja                                         pihaljam@umich.edu 
3. Aaron Robida                                                 bida@umich.edu 
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Suspension Cultures: Orospheres 
 
Materials Required: 
1. Dulbecco’s modified Eagle’s medium Low Glucose (DMEM, Invitrogen) 
with 10% Fetal Bovine Serum (FBS Gibco 10082; Invitrogen), 1% 
Penicillin/Streptomycin or 1% Antibiotic  Antimycotic Solution for primary 
cultures(AAA, Sigma A5955; St. Louis, MO) 
2. Ultra-low attachment plates (Corning 3471; Corning NY) 
 
Procedure: 
1. FACS sorted cells (ALDH+CD44+ and ALDH-CD44-) are seeded as 
triplicates in 6 well Low attachment plates at about 5 103 cells/well in 2-3 
ml of media. 
Note: Use 3 ml if there is no treatment subsequently.  
If you want to treat the cells (for example, endothelial cell CM), suspend 
the cells in 2 ml of media, wait 6 hours in incubation and add 1 ml of 
treatment on top gently without disturbing the cells very much. 
2. Incubate at 37
.
C for 3 days, observe every day with minimal shaking to 
prevent dissociation of the forming spheres.   
3. Orospheres can be seen in 3 days under a light microscope or a phase 
contrast microscope. Orospheres can be quantified by counting the 
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number of spheres/well. Spheres which are smaller than (25-50 cells) are 
not counted. 
 
To generate secondary and tertiary orospheres,  
1. orospheres are dissociated mechanically using a pipette. 
2. Single cell suspensions are again counted and re-seeded in a new 6-well 
Low Attachment Plate 
3. Check under the microscope for thorough dissociation 
4. Observe after 3 days for secondary and tertiary orospheres. 
 
General Instructions: 
1. The time for sphere generation can be cell type specific. Some cell types 
form spheres earlier or later, the average being 2-5 days. 
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Suspension Cultures: Colony Formation Assay 
Materials Required: 
1. Ultrapure Low Melting point agarose (24-28
.
C)(Invitrogen 15517-022; 
Carlsbad, CA) 
2. 10X Minimum Essential Medium (MEM,  Gibco 11430; Invitrogen) 
3. 1X DMEM (no supplements) 
Procedure: 
1. Preparation of 2X DMEM , 2.5% FBS, 1% P/S to make up a volume of 50 
ml. 
a) 5.55 mL of 10X MEM 
b) 2.5 mL of FBS 
c) 1 mL of P/S 
d) 40.95 mL of 1X DMEM 
Mix all the above to obtain 2X DMEM complete media to use. 
2. Preparation of soft agarose plates 
a) Prepare 1.2% and 0.6% agarose solutions, sterilize and store them at 
room temperatures. 
b) Heat the agarose “gels” to melt them in the microwave. 
c) Keep the melted agarose gels in 37
.
C waterbath. 
d) Now, it is ready to use. 
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3. In a 6 well plate, to form the inert feeder layer, for each well, mix 1.5 mL of 
2X DMEM and 1.5 mL of melted 1.2% agarose (equal volumes are 
important). Leave the plates in the hood for 30-40 minutes in the hood for 
the agarose to gel.  
4. Add equal volumes of 2X DMEM (1.5 mL) and 0.6% agarose (1.5 mL) with 
the required cell suspension (approx. 500-5000 cells/well) and add it on to 
the solidified feeder layer. 
Note: the melted agarose should not be too hot when the cells are added 
to ensure cell viability. 
5. Leave the plates again in the hood for 30 minutes to one hour for the 
second layer to solidify. 
6. Add a layer of 1X DMEM on the surface (about 500 µl) to maintain 
moisture. Any treatments like Conditioned Medium can also be added to 
the surface.  
Note: Add treatment or fresh media of about 500 µl every 2-3 days. 
7. Observe the agarose under a light microscope for colonies; colonies 
usually appear in about a week’s time. 
8. The number of colonies in an entire well can be quantified in triplicates 
accordingly.  
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Immunohistochemistry for ALDH1 
Materials  Required: 
1. ALDH1 antibody (BD Biosciences, 61195; Franklin Lakes, NJ) 
2. Deparaffinizing materials (Xylene, Ethanol) 
3. Dako Retrieval Solution 10X (Dako S1699; Carpinteria, CA) 
4. Background Sniper – (Biocare Medical BS99H; Concord, CA) 
5. DAB/AEC Chromogen kits (DAB - DS854H; AEC - RAEC-810; Biocare 
Medical, Concord, CA) 
6. Secondary antibody MACH 3 (MP53G, MH53G, Biocare Medical, 
Concord, CA) 
Procedure: 
1. Bake paraffin embedded sections at 37
.
C for 30 minutes 
2. Bake slides at 59
.
C for 30 minutes. 
3. Xylene 100% - 10 minutes, 2 times. (Please do not change the order of 
the xylenes if being re-used.), check for complete removal of paraffin. 
4. Ethanol – 100% 5 minutes, 2 times 
5. Ethanol -  95% 3 minutes, 1 time 
6. Ethanol -  75% 5 dips 
7. Rinse the slides thoroughly for 5 minutes, 2 times in DDW. 
8. Wash in 1X PBS for 5 minutes. 
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9. Antigen Retrieval Solution: Immerse slides in Dako Retrieval Solution 1X 
solution in a water bath.  
Note: it helps to do slow heating from about 45
.
C – to a maximum of 98
.
C 
over a period of 40-45 minutes. Please do not let the tissue sections to 
boil. 
10. Let the slides cool at room temperature for 20-30 minutes.  
11. Rinse the slides in distilled water. 
12. Circle the tissues with a PAP pen to contain the reagents. 
13. To block for non-specific binding, incubate in 3% hydrogen peroxidase 
(prepared in methanol or PBS), for 6-8 minutes, once. 
14. Rinse the slides in PBS, 5 minutes. 
15. Background Sniper, incubate for 6-8 minutes, once.  
Note: not strictly necessary, use if the tissue sections have too much 
background). 
16. Wash slides with PBS, 5 minutes, twice. 
17. Incubate slides in primary antibody, ALDH1 (1:50) in PBS/diluent solutions 
overnight at 4
.
C.  
 Note: If tissue sections have a good staining, you can go up to 1:100 or 
1:200, but in most hard to stain tissue sections, 1:50 works best.  
18. The next day, wash slides in PBS, 2 times for 10 minutes, with gentle 
shaking. 
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19.  Secondary antibody: mouse probe (room temperature for 20 minutes). 
We use MACH 3 linker (MP530G) from Biocare medical. 
20. Wash 2 times, 10 minutes, in PBS with shaking. 
21.  Mouse-HRP polymer, room temperature for 20 minutes. We use MACH 3 
HRP polymer (MH530G) from Biocare Medical. 
22. Wash slides with PBS, twice 10 minutes, shaking. 
23. Color development (DAB or AEC) 
DAB substrate 1 ml + 1 drop DAB chromogen (Biocare Medical) 
AEC buffer 5 ml + 1 drop Solutions A, B, C (Romulin AEC kit, RAEC 810L) 
Note: AEC and DAB are carcinogenic, please be careful while handling 
them. 
24. Control the staining in the reaction, check for optimal staining in the 
microscope. Stop the reaction immersing the slides in DDW. 
25. Counterstain with Hematoxylin in quick dips and wash with flowing water 
for 15-20 minutes. 
26. Mount the slides with aqueous mounting media and cover with cover 
glass. 
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Preparation of slides for Confocal Imaging 
Materials Required: 
1. Zenon Alexafluor 488 (Molecular Probes, Z25102; Invitrogen) 
2. Zenon Alexafluor 594 (Molecular Probes, Z25007; Invitrogen) 
3. Prolong Gold labeling with DAPI- antifade (Invitrogen P36931) 
4. Deparaffinizing materials (Xylene, Ethanol) 
5. Dako Retrieval Solution 10X (Dako S1699; Carpinteria, CA) 
6. Background Sniper – (Biocare Medical BS99H; Concord, CA) 
7. Antibodies to proteins of interest 
ALDH1     (BD Biosciences, 61195; Franklin Lakes, NJ) 
CD44       (abcam, 51037; San Francisco, CA) 
P-STAT3 (santa cruz, 7993-R; Santa Cruz, CA) 
IL-6R       (abcam, 47173; San Francisco, CA) 
Gp130     (abcam, 59389; San Francisco, CA) 
Procedure: 
1. Bake paraffin embedded sections at 37
.
C for 30 minutes 
2. Bake slides at 59
.
C for 30 minutes. 
3. Xylene 100% - 10 minutes, 2 washes. (Please do not change the order of 
the xylenes if being re-used.), check for complete removal of paraffin. 
4. Ethanol – 100% 5 minutes, 2 washes 
5. Ethanol -  95% 3 minutes, 1 wash 
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6. Ethanol -  75% 5 dips 
7. Rinse the slides thoroughly for 5 minutes, 2 times 
8. Antigen Retrieval Solution: Immerse slides in Dako Retrieval Solution 1X 
solution in a water bath.  
Note: it helps to do slow heating from about 45
.
C – to a maximum of 95
.
-
98
.
C over a period of 40-45 minutes. Please do not let the tissue sections 
to boil. 
9. Let the slides cool at room temperature for 20-30 minutes.  
10. Rinse the slides in distilled water. 
11. To block for non-specific binding, wash in 3% hydrogen peroxidase 
(prepared in methanol and not water), for 6-8 minutes, once. 
12. Rinse the slides in PBS, 5 minutes. 
13. Background Sniper, wash for 6-8 minutes, once.  
Note: not strictly necessary, use if the tissue sections have too much 
background). 
14. Wash slides with PBS, 5 minutes, twice. 
15. Prepare the Zenon complex for labeling antibodies. 
a) Prepare 1 µg of the antibody of interest in PBS, (to approximately 10 µl 
of PBS). 
b) Add 5 µl of the Zenon human IgG labeling reagent A to the antibody 
solution. 
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Note:i) Please take care that if the antibody is mouse, the Zenon labeling is 
mouse as well 
        ii) For different antibodies, use different colors and species of Zenon. 
For example, ALDH1 is mouse antibody and CD44 is rabbit antibody. Use 
green mouse for ALDH1 and red rabbit for CD44 from the Zenon labeling 
kit. 
c) Incubate the mixture for 5 minutes in room temperature  
d) Add 5 µl of the appropriate Component B of the Zenon Labeling kit. 
e) Incubate the mixture for 5 minutes in room temperature.  
Note: The Zenon reagents are fluorochromes; light sensitive, cover the 
tube with aluminium foil during incubation. 
f) The complexes are ready to use. Use within 30 minutes. 
16. Dilute this mixture at the appropriate dilutions (for ALDH1, 1:50; CD44, 
1:200, P-STAT3, 1:200; IL-6R, 1:200, gp130, 1:200) in PBS or diluents 
and add it to the tissue sections. 
17. Cover the slides holder with Aluminium foil (the reagents are light 
sensitive) and incubate in 4
.
C overnight. 
18. The next day, wash the slides with PBS for 15 minutes three times. 
19. Mount the slides with Prolong Gold with DAPI and store in -20C until 
imaging. 
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General Instructions: 
1. The concentration of the antibody needs to be standardized for 
individual antibodies. 
2. Imaging needs to be done as soon as possible. 
3. Depending on the application, use the appropriate scope for confocal. 
For example, single cell co-localizations are best done with the Leica 
Inverted Microscope and the Z-stacking images to study several 
microns of thickness with the Zeiss confocal. 
